search
Back to results

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Primary Purpose

Atrial Fibrillation, Stroke

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
warfarin
Dabigatran dose 1
Dabigatran dose 2
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, TIA, or systemic embolism, left ventricular dysfunction, age >=75 years, age >=65 with either diabetes mellitus, history of coronary artery disease or hypertension) Exclusion criteria Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days Conditions associated with an increased risk of bleeding Contraindication to warfarin treatment Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). Plan to perform a pulmonary vein ablation or surgery for cure of the AF Severe renal impairment (estimated creatinine clearance <=30 mL/min) Active infective endocarditis Active liver disease Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study Anaemia (haemoglobin <100g/L) or thrombocytopenia (platelet count <100 x 109/L) Patients who have developed transaminase elevations upon exposure to ximelagatran Patients who have received an investigational drug in the past 30 days or are participating in another drug study Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse) Any known hypersensitivity to galactose if the warfarin used contains galactose.

Sites / Locations

  • 1160.26.0009 Boehringer Ingelheim Investigational Site
  • 1160.26.0046 Boehringer Ingelheim Investigational Site
  • 1160.26.0057 Boehringer Ingelheim Investigational Site
  • 1160.26.0211 Boehringer Ingelheim Investigational Site
  • 1160.26.0206 Boehringer Ingelheim Investigational Site
  • 1160.26.0115 Boehringer Ingelheim Investigational Site
  • 1160.26.0104 Boehringer Ingelheim Investigational Site
  • 1160.26.0304 Boehringer Ingelheim Investigational Site
  • 1160.26.0185 Boehringer Ingelheim Investigational Site
  • 1160.26.0305 Boehringer Ingelheim Investigational Site
  • 1160.26.0038 Boehringer Ingelheim Investigational Site
  • 1160.26.0302 Boehringer Ingelheim Investigational Site
  • 1160.26.0121 Boehringer Ingelheim Investigational Site
  • 1160.26.0191 Boehringer Ingelheim Investigational Site
  • 1160.26.0204 Boehringer Ingelheim Investigational Site
  • 1160.26.0213 Boehringer Ingelheim Investigational Site
  • 1160.26.0455 Boehringer Ingelheim Investigational Site
  • 1160.26.0388 Boehringer Ingelheim Investigational Site
  • 1160.26.0441 Boehringer Ingelheim Investigational Site
  • 1160.26.0145 Boehringer Ingelheim Investigational Site
  • 1160.26.0333 Boehringer Ingelheim Investigational Site
  • 1160.26.0384 Boehringer Ingelheim Investigational Site
  • 1160.26.0091 Boehringer Ingelheim Investigational Site
  • 1160.26.0246 Boehringer Ingelheim Investigational Site
  • 1160.26.0345 Boehringer Ingelheim Investigational Site
  • 1160.26.0217 Boehringer Ingelheim Investigational Site
  • 1160.26.0059 Boehringer Ingelheim Investigational Site
  • 1160.26.0088 Boehringer Ingelheim Investigational Site
  • 1160.26.0337 Boehringer Ingelheim Investigational Site
  • 1160.26.0326 Boehringer Ingelheim Investigational Site
  • 1160.26.0070 Boehringer Ingelheim Investigational Site
  • 1160.26.0349 Boehringer Ingelheim Investigational Site
  • 1160.26.0016 Boehringer Ingelheim Investigational Site
  • 1160.26.0087 Boehringer Ingelheim Investigational Site
  • 1160.26.0459 Boehringer Ingelheim Investigational Site
  • 1160.26.0216 Boehringer Ingelheim Investigational Site
  • 1160.26.0135 Boehringer Ingelheim Investigational Site
  • 1160.26.0162 Boehringer Ingelheim Investigational Site
  • 1160.26.0300 Boehringer Ingelheim Investigational Site
  • 1160.26.0371 Boehringer Ingelheim Investigational Site
  • 1160.26.0116 Boehringer Ingelheim Investigational Site
  • 1160.26.0148 Boehringer Ingelheim Investigational Site
  • 1160.26.0270 Boehringer Ingelheim Investigational Site
  • 1160.26.0284 Boehringer Ingelheim Investigational Site
  • 1160.26.0351 Boehringer Ingelheim Investigational Site
  • 1160.26.0043 Boehringer Ingelheim Investigational Site
  • 1160.26.0462 Boehringer Ingelheim Investigational Site
  • 1160.26.0276 Boehringer Ingelheim Investigational Site
  • 1160.26.0379 Boehringer Ingelheim Investigational Site
  • 1160.26.0419 Boehringer Ingelheim Investigational Site
  • 1160.26.0321 Boehringer Ingelheim Investigational Site
  • 1160.26.0449 Boehringer Ingelheim Investigational Site
  • 1160.26.0360 Boehringer Ingelheim Investigational Site
  • 1160.26.0413 Boehringer Ingelheim Investigational Site
  • 1160.26.0362 Boehringer Ingelheim Investigational Site
  • 1160.26.0399 Boehringer Ingelheim Investigational Site
  • 1160.26.0058 Boehringer Ingelheim Investigational Site
  • 1160.26.0241 Boehringer Ingelheim Investigational Site
  • 1160.26.0278 Boehringer Ingelheim Investigational Site
  • 1160.26.0085 Boehringer Ingelheim Investigational Site
  • 1160.26.0482 Boehringer Ingelheim Investigational Site
  • 1160.26.0366 Boehringer Ingelheim Investigational Site
  • 1160.26.0343 Boehringer Ingelheim Investigational Site
  • 1160.26.0022 Boehringer Ingelheim Investigational Site
  • 1160.26.0382 Boehringer Ingelheim Investigational Site
  • 1160.26.0056 Boehringer Ingelheim Investigational Site
  • 1160.26.0105 Boehringer Ingelheim Investigational Site
  • 1160.26.0296 Boehringer Ingelheim Investigational Site
  • 1160.26.0429 Boehringer Ingelheim Investigational Site
  • 1160.26.0376 Boehringer Ingelheim Investigational Site
  • 1160.26.0411 Boehringer Ingelheim Investigational Site
  • 1160.26.0074 Boehringer Ingelheim Investigational Site
  • 1160.26.0239 Boehringer Ingelheim Investigational Site
  • 1160.26.0260 Boehringer Ingelheim Investigational Site
  • 1160.26.0265 Boehringer Ingelheim Investigational Site
  • 1160.26.0100 Boehringer Ingelheim Investigational Site
  • 1160.26.0209 Boehringer Ingelheim Investigational Site
  • 1160.26.0033 Boehringer Ingelheim Investigational Site
  • 1160.26.0089 Boehringer Ingelheim Investigational Site
  • 1160.26.0232 Boehringer Ingelheim Investigational Site
  • 1160.26.0240 Boehringer Ingelheim Investigational Site
  • 1160.26.0427 Boehringer Ingelheim Investigational Site
  • 1160.26.0464 Boehringer Ingelheim Investigational Site
  • 1160.26.0012 Boehringer Ingelheim Investigational Site
  • 1160.26.0259 Boehringer Ingelheim Investigational Site
  • 1160.26.0358 Boehringer Ingelheim Investigational Site
  • 1160.26.0034 Boehringer Ingelheim Investigational Site
  • 1160.26.0199 Boehringer Ingelheim Investigational Site
  • 1160.26.0227 Boehringer Ingelheim Investigational Site
  • 1160.26.0095 Boehringer Ingelheim Investigational Site
  • 1160.26.0037 Boehringer Ingelheim Investigational Site
  • 1160.26.0076 Boehringer Ingelheim Investigational Site
  • 1160.26.0081 Boehringer Ingelheim Investigational Site
  • 1160.26.0111 Boehringer Ingelheim Investigational Site
  • 1160.26.0137 Boehringer Ingelheim Investigational Site
  • 1160.26.0389 Boehringer Ingelheim Investigational Site
  • 1160.26.0417 Boehringer Ingelheim Investigational Site
  • 1160.26.0332 Boehringer Ingelheim Investigational Site
  • 1160.26.0226 Boehringer Ingelheim Investigational Site
  • 1160.26.0015 Boehringer Ingelheim Investigational Site
  • 1160.26.0339 Boehringer Ingelheim Investigational Site
  • 1160.26.0031 Boehringer Ingelheim Investigational Site
  • 1160.26.0385 Boehringer Ingelheim Investigational Site
  • 1160.26.0010 Boehringer Ingelheim Investigational Site
  • 1160.26.0327 Boehringer Ingelheim Investigational Site
  • 1160.26.0271 Boehringer Ingelheim Investigational Site
  • 1160.26.0328 Boehringer Ingelheim Investigational Site
  • 1160.26.0381 Boehringer Ingelheim Investigational Site
  • 1160.26.0019 Boehringer Ingelheim Investigational Site
  • 1160.26.0159 Boehringer Ingelheim Investigational Site
  • 1160.26.0283 Boehringer Ingelheim Investigational Site
  • 1160.26.0338 Boehringer Ingelheim Investigational Site
  • 1160.26.0021 Boehringer Ingelheim Investigational Site
  • 1160.26.0319 Boehringer Ingelheim Investigational Site
  • 1160.26.0092 Boehringer Ingelheim Investigational Site
  • 1160.26.0161 Boehringer Ingelheim Investigational Site
  • 1160.26.0026 Boehringer Ingelheim Investigational Site
  • 1160.26.0218 Boehringer Ingelheim Investigational Site
  • 1160.26.0184 Boehringer Ingelheim Investigational Site
  • 1160.26.0233 Boehringer Ingelheim Investigational Site
  • 1160.26.0324 Boehringer Ingelheim Investigational Site
  • 1160.26.0457 Boehringer Ingelheim Investigational Site
  • 1160.26.0237 Boehringer Ingelheim Investigational Site
  • 1160.26.0236 Boehringer Ingelheim Investigational Site
  • 1160.26.0396 Boehringer Ingelheim Investigational Site
  • 1160.26.0438 Boehringer Ingelheim Investigational Site
  • 1160.26.0331 Boehringer Ingelheim Investigational Site
  • 1160.26.0364 Boehringer Ingelheim Investigational Site
  • 1160.26.0109 Boehringer Ingelheim Investigational Site
  • 1160.26.0152 Boehringer Ingelheim Investigational Site
  • 1160.26.0198 Boehringer Ingelheim Investigational Site
  • 1160.26.0433 Boehringer Ingelheim Investigational Site
  • 1160.26.0041 Boehringer Ingelheim Investigational Site
  • 1160.26.0377 Boehringer Ingelheim Investigational Site
  • 1160.26.0288 Boehringer Ingelheim Investigational Site
  • 1160.26.0352 Boehringer Ingelheim Investigational Site
  • 1160.26.0436 Boehringer Ingelheim Investigational Site
  • 1160.26.0028 Boehringer Ingelheim Investigational Site
  • 1160.26.0235 Boehringer Ingelheim Investigational Site
  • 1160.26.0268 Boehringer Ingelheim Investigational Site
  • 1160.26.0001 Boehringer Ingelheim Investigational Site
  • 1160.26.0189 Boehringer Ingelheim Investigational Site
  • 1160.26.0357 Boehringer Ingelheim Investigational Site
  • 1160.26.0354 Boehringer Ingelheim Investigational Site
  • 1160.26.0077 Boehringer Ingelheim Investigational Site
  • 1160.26.0138 Boehringer Ingelheim Investigational Site
  • 1160.26.0422 Boehringer Ingelheim Investigational Site
  • 1160.26.0178 Boehringer Ingelheim Investigational Site
  • 1160.26.0397 Boehringer Ingelheim Investigational Site
  • 1160.26.0310 Boehringer Ingelheim Investigational Site
  • 1160.26.0011 Boehringer Ingelheim Investigational Site
  • 1160.26.0144 Boehringer Ingelheim Investigational Site
  • 1160.26.0404 Boehringer Ingelheim Investigational Site
  • 1160.26.0093 Boehringer Ingelheim Investigational Site
  • 1160.26.0340 Boehringer Ingelheim Investigational Site
  • 1160.26.0018 Boehringer Ingelheim Investigational Site
  • 1160.26.0391 Boehringer Ingelheim Investigational Site
  • 1160.26.0252 Boehringer Ingelheim Investigational Site
  • 1160.26.0132 Boehringer Ingelheim Investigational Site
  • 1160.26.0299 Tulane University School Of Medicine
  • 1160.26.0048 Boehringer Ingelheim Investigational Site
  • 1160.26.0096 Boehringer Ingelheim Investigational Site
  • 1160.26.0068 Boehringer Ingelheim Investigational Site
  • 1160.26.0114 Boehringer Ingelheim Investigational Site
  • 1160.26.0164 Boehringer Ingelheim Investigational Site
  • 1160.26.0023 Boehringer Ingelheim Investigational Site
  • 1160.26.0047 Boehringer Ingelheim Investigational Site
  • 1160.26.0079 Boehringer Ingelheim Investigational Site
  • 1160.26.0186 Boehringer Ingelheim Investigational Site
  • 1160.26.0194 Boehringer Ingelheim Investigational Site
  • 1160.26.0255 Boehringer Ingelheim Investigational Site
  • 1160.26.0398 Boehringer Ingelheim Investigational Site
  • 1160.26.0177 Boehringer Ingelheim Investigational Site
  • 1160.26.0073 Boehringer Ingelheim Investigational Site
  • 1160.26.0207 Boehringer Ingelheim Investigational Site
  • 1160.26.0196 Boehringer Ingelheim Investigational Site
  • 1160.26.0187 Boehringer Ingelheim Investigational Site
  • 1160.26.0052 Boehringer Ingelheim Investigational Site
  • 1160.26.0042 Boehringer Ingelheim Investigational Site
  • 1160.26.0401 Boehringer Ingelheim Investigational Site
  • 1160.26.0160 Boehringer Ingelheim Investigational Site
  • 1160.26.0443 Boehringer Ingelheim Investigational Site
  • 1160.26.0452 Boehringer Ingelheim Investigational Site
  • 1160.26.0029 Boehringer Ingelheim Investigational Site
  • 1160.26.0446 Boehringer Ingelheim Investigational Site
  • 1160.26.0003 Boehringer Ingelheim Investigational Site
  • 1160.26.0470 Boehringer Ingelheim Investigational Site
  • 1160.26.0308 Boehringer Ingelheim Investigational Site
  • 1160.26.0141 Boehringer Ingelheim Investigational Site
  • 1160.26.0225 Boehringer Ingelheim Investigational Site
  • 1160.26.0154 Boehringer Ingelheim Investigational Site
  • 1160.26.0030 Boehringer Ingelheim Investigational Site
  • 1160.26.0171 Boehringer Ingelheim Investigational Site
  • 1160.26.0205 Boehringer Ingelheim Investigational Site
  • 1160.26.0279 Boehringer Ingelheim Investigational Site
  • 1160.26.0445 Boehringer Ingelheim Investigational Site
  • 1160.26.0274 Boehringer Ingelheim Investigational Site
  • 1160.26.0165 Boehringer Ingelheim Investigational Site
  • 1160.26.0020 Boehringer Ingelheim Investigational Site
  • 1160.26.0188 Boehringer Ingelheim Investigational Site
  • 1160.26.0131 Boehringer Ingelheim Investigational Site
  • 1160.26.0421 Boehringer Ingelheim Investigational Site
  • 1160.26.0202 Boehringer Ingelheim Investigational Site
  • 1160.26.0101 Boehringer Ingelheim Investigational Site
  • 1160.26.0086 Boehringer Ingelheim Investigational Site
  • 1160.26.0119 Boehringer Ingelheim Investigational Site
  • 1160.26.0055 Boehringer Ingelheim Investigational Site
  • 1160.26.0172 Boehringer Ingelheim Investigational Site
  • 1160.26.0257 Boehringer Ingelheim Investigational Site
  • 1160.26.0266 Boehringer Ingelheim Investigational Site
  • 1160.26.0336 Boehringer Ingelheim Investigational Site
  • 1160.26.0249 Boehringer Ingelheim Investigational Site
  • 1160.26.0027 Boehringer Ingelheim Investigational Site
  • 1160.26.0128 Boehringer Ingelheim Investigational Site
  • 1160.26.0110 Boehringer Ingelheim Investigational Site
  • 1160.26.0355 Boehringer Ingelheim Investigational Site
  • 1160.26.0346 Boehringer Ingelheim Investigational Site
  • 1160.26.0066 Boehringer Ingelheim Investigational Site
  • 1160.26.0174 Boehringer Ingelheim Investigational Site
  • 1160.26.0430 Boehringer Ingelheim Investigational Site
  • 1160.26.0190 Boehringer Ingelheim Investigational Site
  • 1160.26.0142 Boehringer Ingelheim Investigational Site
  • 1160.26.0125 Boehringer Ingelheim Investigational Site
  • 1160.26.0432 Boehringer Ingelheim Investigational Site
  • 1160.26.0448 Boehringer Ingelheim Investigational Site
  • 1160.26.0248 Boehringer Ingelheim Investigational Site
  • 1160.26.0244 Boehringer Ingelheim Investigational Site
  • 1160.26.0243 Boehringer Ingelheim Investigational Site
  • 1160.26.0478 Boehringer Ingelheim Investigational Site
  • 1160.26.0392 Boehringer Ingelheim Investigational Site
  • 1160.26.0472 Boehringer Ingelheim Investigational Site
  • 1160.26.0221 Boehringer Ingelheim Investigational Site
  • 1160.26.0254 Boehringer Ingelheim Investigational Site
  • 1160.26.0127 Boehringer Ingelheim Investigational Site
  • 1160.26.0423 Boehringer Ingelheim Investigational Site
  • 1160.26.0476 Boehringer Ingelheim Investigational Site
  • 1160.26.0113 Boehringer Ingelheim Investigational Site
  • 1160.26.0281 Boehringer Ingelheim Investigational Site
  • 1160.26.0063 Boehringer Ingelheim Investigational Site
  • 1160.26.0044 Boehringer Ingelheim Investigational Site
  • 1160.26.0373 Boehringer Ingelheim Investigational Site
  • 1160.26.0045 Boehringer Ingelheim Investigational Site
  • 1160.26.0251 Boehringer Ingelheim Investigational Site
  • 1160.26.0229 Boehringer Ingelheim Investigational Site
  • 1160.26.0451 Boehringer Ingelheim Investigational Site
  • 1160.26.0090 Boehringer Ingelheim Investigational Site
  • 1160.26.0183 Boehringer Ingelheim Investigational Site
  • 1160.26.0316 Boehringer Ingelheim Investigational Site
  • 1160.26.0146 Boehringer Ingelheim Investigational Site
  • 1160.26.0210 Boehringer Ingelheim Investigational Site
  • 1160.26.0075 Boehringer Ingelheim Investigational Site
  • 1160.26.0197 Boehringer Ingelheim Investigational Site
  • 1160.26.0320 Boehringer Ingelheim Investigational Site
  • 1160.26.0064 Boehringer Ingelheim Investigational Site
  • 1160.26.0414 Boehringer Ingelheim Investigational Site
  • 1160.26.0356 Boehringer Ingelheim Investigational Site
  • 1160.26.0039 Boehringer Ingelheim Investigational Site
  • 1160.26.0353 Boehringer Ingelheim Investigational Site
  • 1160.26.0080 Boehringer Ingelheim Investigational Site
  • 1160.26.0412 Boehringer Ingelheim Investigational Site
  • 1160.26.0350 Boehringer Ingelheim Investigational Site
  • 1160.26.0322 Boehringer Ingelheim Investigational Site
  • 1160.26.0173 Boehringer Ingelheim Investigational Site
  • 1160.26.0108 Boehringer Ingelheim Investigational Site
  • 1160.26.0006 Boehringer Ingelheim Investigational Site
  • 1160.26.0002 Boehringer Ingelheim Investigational Site
  • 1160.26.0069 Boehringer Ingelheim Investigational Site
  • 1160.26.0372 Boehringer Ingelheim Investigational Site
  • 1160.26.0094 Boehringer Ingelheim Investigational Site
  • 1160.26.0425 Boehringer Ingelheim Investigational Site
  • 1160.26.0102 Boehringer Ingelheim Investigational Site
  • 1160.26.0222 Boehringer Ingelheim Investigational Site
  • 1160.26.0203 Boehringer Ingelheim Investigational Site
  • 1160.26.0434 Boehringer Ingelheim Investigational Site
  • 1160.26.0083 Boehringer Ingelheim Investigational Site
  • 1160.26.0402 Boehringer Ingelheim Investigational Site
  • 1160.26.0426 Boehringer Ingelheim Investigational Site
  • 1160.26.0479 Boehringer Ingelheim Investigational Site
  • 1160.26.0263 Boehringer Ingelheim Investigational Site
  • 1160.26.0480 Boehringer Ingelheim Investigational Site
  • 1160.26.0267 Boehringer Ingelheim Investigational Site
  • 1160.26.0035 Boehringer Ingelheim Investigational Site
  • 1160.26.0150 Boehringer Ingelheim Investigational Site
  • 1160.26.0201 Boehringer Ingelheim Investigational Site
  • 1160.26.0223 Boehringer Ingelheim Investigational Site
  • 1160.26.0214 Boehringer Ingelheim Investigational Site
  • 1160.26.0275 Boehringer Ingelheim Investigational Site
  • 1160.26.0103 Boehringer Ingelheim Investigational Site
  • 1160.26.0155 Boehringer Ingelheim Investigational Site
  • 1160.26.0435 Boehringer Ingelheim Investigational Site
  • 1160.26.0139 Boehringer Ingelheim Investigational Site
  • 1160.26.0325 Boehringer Ingelheim Investigational Site
  • 1160.26.0078 Boehringer Ingelheim Investigational Site
  • 1160.26.0245 Boehringer Ingelheim Investigational Site
  • 1160.26.0133 Boehringer Ingelheim Investigational Site
  • 1160.26.0301 Boehringer Ingelheim Investigational Site
  • 1160.26.0454 Boehringer Ingelheim Investigational Site
  • 1160.26.0295 Boehringer Ingelheim Investigational Site
  • 1160.26.0294 Boehringer Ingelheim Investigational Site
  • 1160.26.0369 Boehringer Ingelheim Investigational Site
  • 1160.26.0303 Boehringer Ingelheim Investigational Site
  • 1160.26.0431 Boehringer Ingelheim Investigational Site
  • 1160.26.0168 Boehringer Ingelheim Investigational Site
  • 1160.26.0293 Boehringer Ingelheim Investigational Site
  • 1160.26.0025 Boehringer Ingelheim Investigational Site
  • 1160.26.0394 Boehringer Ingelheim Investigational Site
  • 1160.26.0158 Boehringer Ingelheim Investigational Site
  • 1160.26.0181 Boehringer Ingelheim Investigational Site
  • 1160.26.0416 Boehringer Ingelheim Investigational Site
  • 1160.26.0344 Boehringer Ingelheim Investigational Site
  • 1160.26.0466 Boehringer Ingelheim Investigational Site
  • 1160.26.0208 Boehringer Ingelheim Investigational Site
  • 1160.26.0465 Boehringer Ingelheim Investigational Site
  • 1160.26.0400 Boehringer Ingelheim Investigational Site
  • 1160.26.0032 Boehringer Ingelheim Investigational Site
  • 1160.26.0067 Boehringer Ingelheim Investigational Site
  • 1160.26.0212 Boehringer Ingelheim Investigational Site
  • 1160.26.0007 Boehringer Ingelheim Investigational Site
  • 1160.26.0383 Boehringer Ingelheim Investigational Site
  • 1160.26.0313 Boehringer Ingelheim Investigational Site
  • 1160.26.0450 Boehringer Ingelheim Investigational Site
  • 1160.26.0166 Boehringer Ingelheim Investigational Site
  • 1160.26.0008 Boehringer Ingelheim Investigational Site
  • 1160.26.0468 Boehringer Ingelheim Investigational Site
  • 1160.26.0348 Boehringer Ingelheim Investigational Site
  • 1160.26.0084 Boehringer Ingelheim Investigational Site
  • 1160.26.0062 Boehringer Ingelheim Investigational Site
  • 1160.26.0370 Boehringer Ingelheim Investigational Site
  • 1160.26.0323 Boehringer Ingelheim Investigational Site
  • 1160.26.0395 Boehringer Ingelheim Investigational Site
  • 1160.26.0474 Boehringer Ingelheim Investigational Site
  • 1160.26.0129 Boehringer Ingelheim Investigational Site
  • 1160.26.0410 Boehringer Ingelheim Investigational Site
  • 1160.26.0156 Boehringer Ingelheim Investigational Site
  • 1160.26.0315 Boehringer Ingelheim Investigational Site
  • 1160.26.0444 Boehringer Ingelheim Investigational Site
  • 1160.26.0447 Boehringer Ingelheim Investigational Site
  • 1160.26.0483 Boehringer Ingelheim Investigational Site
  • 1160.26.0335 Boehringer Ingelheim Investigational Site
  • 1160.26.0230 Boehringer Ingelheim Investigational Site
  • 1160.26.0467 Boehringer Ingelheim Investigational Site
  • 1160.26.0013 Boehringer Ingelheim Investigational Site
  • 1160.26.0269 Boehringer Ingelheim Investigational Site
  • 1160.26.0307 Boehringer Ingelheim Investigational Site
  • 1160.26.0285 Boehringer Ingelheim Investigational Site
  • 1160.26.0215 Boehringer Ingelheim Investigational Site
  • 1160.26.0367 Boehringer Ingelheim Investigational Site
  • 1160.26.0195 Boehringer Ingelheim Investigational Site
  • 1160.26.0453 Boehringer Ingelheim Investigational Site
  • 1160.26.0053 Boehringer Ingelheim Investigational Site
  • 1160.26.0098 Boehringer Ingelheim Investigational Site
  • 1160.26.0386 Boehringer Ingelheim Investigational Site
  • 1160.26.0428 Boehringer Ingelheim Investigational Site
  • 1160.26.0311 Boehringer Ingelheim Investigational Site
  • 1160.26.0292 Boehringer Ingelheim Investigational Site
  • 1160.26.0224 Boehringer Ingelheim Investigational Site
  • 1160.26.0220 Boehringer Ingelheim Investigational Site
  • 1160.26.0317 Boehringer Ingelheim Investigational Site
  • 1160.26.0287 Boehringer Ingelheim Investigational Site
  • 1160.26.0050 Boehringer Ingelheim Investigational Site
  • 1160.26.0040 Boehringer Ingelheim Investigational Site
  • 1160.26.0298 Boehringer Ingelheim Investigational Site
  • 1160.26.0250 Boehringer Ingelheim Investigational Site
  • 1160.26.0256 Boehringer Ingelheim Investigational Site
  • 1160.26.0024 Boehringer Ingelheim Investigational Site
  • 1160.26.0193 Boehringer Ingelheim Investigational Site
  • 1160.26.0169 Boehringer Ingelheim Investigational Site
  • 1160.26.0365 Boehringer Ingelheim Investigational Site
  • 1160.26.0072 Boehringer Ingelheim Investigational Site
  • 1160.26.0234 Boehringer Ingelheim Investigational Site
  • 1160.26.0099 Boehringer Ingelheim Investigational Site
  • 1160.26.0242 Boehringer Ingelheim Investigational Site
  • 1160.26.0359 Boehringer Ingelheim Investigational Site
  • 1160.26.0461 Boehringer Ingelheim Investigational Site
  • 1160.26.0523 Boehringer Ingelheim Investigational Site
  • 1160.26.0524 Boehringer Ingelheim Investigational Site
  • 1160.26.0533 Boehringer Ingelheim Investigational Site
  • 1160.26.0526 Boehringer Ingelheim Investigational Site
  • 1160.26.0529 Boehringer Ingelheim Investigational Site
  • 1160.26.0531 Boehringer Ingelheim Investigational Site
  • 1160.26.0530 Boehringer Ingelheim Investigational Site
  • 1160.26.0527 Boehringer Ingelheim Investigational Site
  • 1160.26.0532 Boehringer Ingelheim Investigational Site
  • 1160.26.0525 Boehringer Ingelheim Investigational Site
  • 1160.26.0521 Boehringer Ingelheim Investigational Site
  • 1160.26.0528 Boehringer Ingelheim Investigational Site
  • 1160.26.0522 Boehringer Ingelheim Investigational Site
  • 1160.26.0508 Boehringer Ingelheim Investigational Site
  • 1160.26.0510 Boehringer Ingelheim Investigational Site
  • 1160.26.0505 Boehringer Ingelheim Investigational Site
  • 1160.26.0506 Boehringer Ingelheim Investigational Site
  • 1160.26.0509 Boehringer Ingelheim Investigational Site
  • 1160.26.0507 Boehringer Ingelheim Investigational Site
  • 1160.26.0504 Boehringer Ingelheim Investigational Site
  • 1160.26.0501 Boehringer Ingelheim Investigational Site
  • 1160.26.0502 Boehringer Ingelheim Investigational Site
  • 1160.26.0503 Boehringer Ingelheim Investigational Site
  • 1160.26.0543 Boehringer Ingelheim Investigational Site
  • 1160.26.0549 Boehringer Ingelheim Investigational Site
  • 1160.26.0546 Boehringer Ingelheim Investigational Site
  • 1160.26.0541 Boehringer Ingelheim Investigational Site
  • 1160.26.0542 Boehringer Ingelheim Investigational Site
  • 1160.26.0544 Boehringer Ingelheim Investigational Site
  • 1160.26.0545 Boehringer Ingelheim Investigational Site
  • 1160.26.0547 Boehringer Ingelheim Investigational Site
  • 1160.26.0548 Boehringer Ingelheim Investigational Site
  • 1160.26.0550 Boehringer Ingelheim Investigational Site
  • 1160.26.0564 Boehringer Ingelheim Investigational Site
  • 1160.26.0573 Boehringer Ingelheim Investigational Site
  • 1160.26.0575 Boehringer Ingelheim Investigational Site
  • 1160.26.0572 Boehringer Ingelheim Investigational Site
  • 1160.26.0577 Boehringer Ingelheim Investigational Site
  • 1160.26.0571 Boehringer Ingelheim Investigational Site
  • 1160.26.0581 Boehringer Ingelheim Investigational Site
  • 1160.26.0585 Boehringer Ingelheim Investigational Site
  • 1160.26.0586 Boehringer Ingelheim Investigational Site
  • 1160.26.0563 Boehringer Ingelheim Investigational Site
  • 1160.26.0578 Boehringer Ingelheim Investigational Site
  • 1160.26.0587 Boehringer Ingelheim Investigational Site
  • 1160.26.0574 Boehringer Ingelheim Investigational Site
  • 1160.26.0588 Boehringer Ingelheim Investigational Site
  • 1160.26.0580 Boehringer Ingelheim Investigational Site
  • 1160.26.0568 Boehringer Ingelheim Investigational Site
  • 1160.26.0569 Boehringer Ingelheim Investigational Site
  • 1160.26.0561 Boehringer Ingelheim Investigational Site
  • 1160.26.0579 Boehringer Ingelheim Investigational Site
  • 1160.26.0583 Boehringer Ingelheim Investigational Site
  • 1160.26.0589 Boehringer Ingelheim Investigational Site
  • 1160.26.0567 Boehringer Ingelheim Investigational Site
  • 1160.26.0570 Boehringer Ingelheim Investigational Site
  • 1160.26.0566 Boehringer Ingelheim Investigational Site
  • 1160.26.0562 Boehringer Ingelheim Investigational Site
  • 1160.26.550648 Boehringer Ingelheim Investigational Site
  • 1160.26.550654 Boehringer Ingelheim Investigational Site
  • 1160.26.550644 Boehringer Ingelheim Investigational Site
  • 1160.26.550650 Boehringer Ingelheim Investigational Site
  • 1160.26.550651 Boehringer Ingelheim Investigational Site
  • 1160.26.550653 Boehringer Ingelheim Investigational Site
  • 1160.26.550652 Boehringer Ingelheim Investigational Site
  • 1160.26.550645 Boehringer Ingelheim Investigational Site
  • 1160.26.550646 Boehringer Ingelheim Investigational Site
  • 1160.26.550647 Boehringer Ingelheim Investigational Site
  • 1160.26.550641 Boehringer Ingelheim Investigational Site
  • 1160.26.550642 Boehringer Ingelheim Investigational Site
  • 1160.26.550643 Boehringer Ingelheim Investigational Site
  • 1160.26.550649 Boehringer Ingelheim Investigational Site
  • 1160.26.0620 Boehringer Ingelheim Investigational Site
  • 1160.26.0611 Boehringer Ingelheim Investigational Site
  • 1160.26.0612 Boehringer Ingelheim Investigational Site
  • 1160.26.0613 Boehringer Ingelheim Investigational Site
  • 1160.26.0614 Boehringer Ingelheim Investigational Site
  • 1160.26.0615 Boehringer Ingelheim Investigational Site
  • 1160.26.0616 Boehringer Ingelheim Investigational Site
  • 1160.26.0617 Boehringer Ingelheim Investigational Site
  • 1160.26.0618 Boehringer Ingelheim Investigational Site
  • 1160.26.0622 Boehringer Ingelheim Investigational Site
  • 1160.26.0623 Boehringer Ingelheim Investigational Site
  • 1160.26.0624 Boehringer Ingelheim Investigational Site
  • 1160.26.0625 Boehringer Ingelheim Investigational Site
  • 1160.26.0626 Boehringer Ingelheim Investigational Site
  • 1160.26.0621 Boehringer Ingelheim Investigational Site
  • 1160.26.0694 Boehringer Ingelheim Investigational Site
  • 1160.26.0696 Boehringer Ingelheim Investigational Site
  • 1160.26.0680 Boehringer Ingelheim Investigational Site
  • 1160.26.0712 Boehringer Ingelheim Investigational Site
  • 1160.26.0706 Boehringer Ingelheim Investigational Site
  • 1160.26.0725 Boehringer Ingelheim Investigational Site
  • 1160.26.0691 Boehringer Ingelheim Investigational Site
  • 1160.26.0714 Boehringer Ingelheim Investigational Site
  • 1160.26.0701 Boehringer Ingelheim Investigational Site
  • 1160.26.0698 Boehringer Ingelheim Investigational Site
  • 1160.26.0707 Boehringer Ingelheim Investigational Site
  • 1160.26.0676 Boehringer Ingelheim Investigational Site
  • 1160.26.0703 Boehringer Ingelheim Investigational Site
  • 1160.26.0679 Boehringer Ingelheim Investigational Site
  • 1160.26.0677 Boehringer Ingelheim Investigational Site
  • 1160.26.0674 Boehringer Ingelheim Investigational Site
  • 1160.26.0702 Boehringer Ingelheim Investigational Site
  • 1160.26.0720 Boehringer Ingelheim Investigational Site
  • 1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
  • 1160.26.0692 Boehringer Ingelheim Investigational Site
  • 1160.26.0685 Boehringer Ingelheim Investigational Site
  • 1160.26.0697 Boehringer Ingelheim Investigational Site
  • 1160.26.0710 Boehringer Ingelheim Investigational Site
  • 1160.26.0719 Boehringer Ingelheim Investigational Site
  • 1160.26.0721 Boehringer Ingelheim Investigational Site
  • 1160.26.0689 Boehringer Ingelheim Investigational Site
  • 1160.26.0695 Boehringer Ingelheim Investigational Site
  • 1160.26.0708 Boehringer Ingelheim Investigational Site
  • 1160.26.0724 Boehringer Ingelheim Investigational Site
  • 1160.26.0688 Boehringer Ingelheim Investigational Site
  • 1160.26.0672 Boehringer Ingelheim Investigational Site
  • 1160.26.0687 Boehringer Ingelheim Investigational Site
  • 1160.26.0723 Boehringer Ingelheim Investigational Site
  • 1160.26.0715 Boehringer Ingelheim Investigational Site
  • 1160.26.0690 Boehringer Ingelheim Investigational Site
  • 1160.26.0684 Boehringer Ingelheim Investigational Site
  • 1160.26.0718 Boehringer Ingelheim Investigational Site
  • 1160.26.0711 Boehringer Ingelheim Investigational Site
  • 1160.26.0686 Boehringer Ingelheim Investigational Site
  • 1160.26.0693 Boehringer Ingelheim Investigational Site
  • 1160.26.0681 Boehringer Ingelheim Investigational Site
  • 1160.26.0683 Boehringer Ingelheim Investigational Site
  • 1160.26.0705 Boehringer Ingelheim Investigational Site
  • 1160.26.0709 Boehringer Ingelheim Investigational Site
  • 1160.26.0716 Boehringer Ingelheim Investigational Site
  • 1160.26.0717 Boehringer Ingelheim Investigational Site
  • 1160.26.0713 Boehringer Ingelheim Investigational Site
  • 1160.26.0704 Boehringer Ingelheim Investigational Site
  • 1160.26.0699 Boehringer Ingelheim Investigational Site
  • 1160.26.0675 Boehringer Ingelheim Investigational Site
  • 1160.26.0700 Boehringer Ingelheim Investigational Site
  • 1160.26.0682 Boehringer Ingelheim Investigational Site
  • 1160.26.0673 Boehringer Ingelheim Investigational Site
  • 1160.26.0678 Boehringer Ingelheim Investigational Site
  • 1160.26.0771 Boehringer Ingelheim Investigational Site
  • 1160.26.0772 Boehringer Ingelheim Investigational Site
  • 1160.26.0773 Boehringer Ingelheim Investigational Site
  • 1160.26.0774 Boehringer Ingelheim Investigational Site
  • 1160.26.0775 Boehringer Ingelheim Investigational Site
  • 1160.26.0783 Boehringer Ingelheim Investigational Site
  • 1160.26.0784 Boehringer Ingelheim Investigational Site
  • 1160.26.0776 Boehringer Ingelheim Investigational Site
  • 1160.26.0778 Boehringer Ingelheim Investigational Site
  • 1160.26.0781 Boehringer Ingelheim Investigational Site
  • 1160.26.0782 Boehringer Ingelheim Investigational Site
  • 1160.26.0777 Boehringer Ingelheim Investigational Site
  • 1160.26.0780 Boehringer Ingelheim Investigational Site
  • 1160.26.0801 Boehringer Ingelheim Investigational Site
  • 1160.26.0802 Boehringer Ingelheim Investigational Site
  • 1160.26.0803 Boehringer Ingelheim Investigational Site
  • 1160.26.0815 Boehringer Ingelheim Investigational Site
  • 1160.26.0816 Boehringer Ingelheim Investigational Site
  • 1160.26.0820 Boehringer Ingelheim Investigational Site
  • 1160.26.0818 Boehringer Ingelheim Investigational Site
  • 1160.26.0814 Boehringer Ingelheim Investigational Site
  • 1160.26.0813 Boehringer Ingelheim Investigational Site
  • 1160.26.0811 Boehringer Ingelheim Investigational Site
  • 1160.26.0812 Boehringer Ingelheim Investigational Site
  • 1160.26.0817 Boehringer Ingelheim Investigational Site
  • 1160.26.0819 Boehringer Ingelheim Investigational Site
  • 1160.26.0837 Boehringer Ingelheim Investigational Site
  • 1160.26.0835 Boehringer Ingelheim Investigational Site
  • 1160.26.0838 Boehringer Ingelheim Investigational Site
  • 1160.26.0833 Boehringer Ingelheim Investigational Site
  • 1160.26.0834 Boehringer Ingelheim Investigational Site
  • 1160.26.0841 Boehringer Ingelheim Investigational Site
  • 1160.26.0832 Boehringer Ingelheim Investigational Site
  • 1160.26.0840 Boehringer Ingelheim Investigational Site
  • 1160.26.0831 Boehringer Ingelheim Investigational Site
  • 1160.26.0839 Boehringer Ingelheim Investigational Site
  • 1160.26.0836 Boehringer Ingelheim Investigational Site
  • 1160.26.0856 Boehringer Ingelheim Investigational Site
  • 1160.26.0851 Boehringer Ingelheim Investigational Site
  • 1160.26.0859 Boehringer Ingelheim Investigational Site
  • 1160.26.0855 Boehringer Ingelheim Investigational Site
  • 1160.26.0857 Boehringer Ingelheim Investigational Site
  • 1160.26.0854 Boehringer Ingelheim Investigational Site
  • 1160.26.0858 Boehringer Ingelheim Investigational Site
  • 1160.26.0852 Boehringer Ingelheim Investigational Site
  • 1160.26.0853 Boehringer Ingelheim Investigational Site
  • 1160.26.0875A Boehringer Ingelheim Investigational Site
  • 1160.26.0882A Boehringer Ingelheim Investigational Site
  • 1160.26.0882B Boehringer Ingelheim Investigational Site
  • 1160.26.0882C Boehringer Ingelheim Investigational Site
  • 1160.26.0882D Boehringer Ingelheim Investigational Site
  • 1160.26.0882E Boehringer Ingelheim Investigational Site
  • 1160.26.0882G Boehringer Ingelheim Investigational Site
  • 1160.26.0882H Boehringer Ingelheim Investigational Site
  • 1160.26.0882I Boehringer Ingelheim Investigational Site
  • 1160.26.0882K Boehringer Ingelheim Investigational Site
  • 1160.26.0882L Boehringer Ingelheim Investigational Site
  • 1160.26.0884A Boehringer Ingelheim Investigational Site
  • 1160.26.0887A Boehringer Ingelheim Investigational Site
  • 1160.26.0889A Boehringer Ingelheim Investigational Site
  • 1160.26.0888A Boehringer Ingelheim Investigational Site
  • 1160.26.0879A Boehringer Ingelheim Investigational Site
  • 1160.26.0879B Boehringer Ingelheim Investigational Site
  • 1160.26.0879C Boehringer Ingelheim Investigational Site
  • 1160.26.0879E Boehringer Ingelheim Investigational Site
  • 1160.26.0879F Boehringer Ingelheim Investigational Site
  • 1160.26.0879G Boehringer Ingelheim Investigational Site
  • 1160.26.0879H Boehringer Ingelheim Investigational Site
  • 1160.26.0879S Boehringer Ingelheim Investigational Site
  • 1160.26.0880A Boehringer Ingelheim Investigational Site
  • 1160.26.0880F Boehringer Ingelheim Investigational Site
  • 1160.26.0880G Boehringer Ingelheim Investigational Site
  • 1160.26.0880J Boehringer Ingelheim Investigational Site
  • 1160.26.0881A Boehringer Ingelheim Investigational Site
  • 1160.26.0881D Boehringer Ingelheim Investigational Site
  • 1160.26.0880B Boehringer Ingelheim Investigational Site
  • 1160.26.0880C Boehringer Ingelheim Investigational Site
  • 1160.26.0880D Boehringer Ingelheim Investigational Site
  • 1160.26.0880E Boehringer Ingelheim Investigational Site
  • 1160.26.0874A Boehringer Ingelheim Investigational Site
  • 1160.26.0874B Boehringer Ingelheim Investigational Site
  • 1160.26.0871A Boehringer Ingelheim Investigational Site
  • 1160.26.0873A Boehringer Ingelheim Investigational Site
  • 1160.26.0886A Boehringer Ingelheim Investigational Site
  • 1160.26.0872A Boehringer Ingelheim Investigational Site
  • 1160.26.0872C Boehringer Ingelheim Investigational Site
  • 1160.26.0872B Boehringer Ingelheim Investigational Site
  • 1160.26.0932 Boehringer Ingelheim Investigational Site
  • 1160.26.0948 Boehringer Ingelheim Investigational Site
  • 1160.26.0962 Boehringer Ingelheim Investigational Site
  • 1160.26.0940 Boehringer Ingelheim Investigational Site
  • 1160.26.0936 Boehringer Ingelheim Investigational Site
  • 1160.26.0968 Boehringer Ingelheim Investigational Site
  • 1160.26.0972 Boehringer Ingelheim Investigational Site
  • 1160.26.0957 Boehringer Ingelheim Investigational Site
  • 1160.26.0971 Boehringer Ingelheim Investigational Site
  • 1160.26.0965 Boehringer Ingelheim Investigational Site
  • 1160.26.0934 Boehringer Ingelheim Investigational Site
  • 1160.26.0931 Boehringer Ingelheim Investigational Site
  • 1160.26.0943 Boehringer Ingelheim Investigational Site
  • 1160.26.0955 Boehringer Ingelheim Investigational Site
  • 1160.26.0963 Boehringer Ingelheim Investigational Site
  • 1160.26.0946 Boehringer Ingelheim Investigational Site
  • 1160.26.0944 Boehringer Ingelheim Investigational Site
  • 1160.26.0951 Boehringer Ingelheim Investigational Site
  • 1160.26.0933 Boehringer Ingelheim Investigational Site
  • 1160.26.0945 Boehringer Ingelheim Investigational Site
  • 1160.26.0970 Boehringer Ingelheim Investigational Site
  • 1160.26.0947 Boehringer Ingelheim Investigational Site
  • 1160.26.0952 Boehringer Ingelheim Investigational Site
  • 1160.26.0941 Boehringer Ingelheim Investigational Site
  • 1160.26.0959 Boehringer Ingelheim Investigational Site
  • 1160.26.0937 Boehringer Ingelheim Investigational Site
  • 1160.26.0966 Boehringer Ingelheim Investigational Site
  • 1160.26.0908 University Hospital of Alexandroupolis
  • 1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
  • 1160.26.0906 General Hospital ";Evangelismos"
  • 1160.26.0907 "Pammakaristos" Hospital of Athens
  • 1160.26.0915 "Hippokratio" Hospital of Athens
  • 1160.26.0914 2nd IKA Hospital, Thessaloniki
  • 1160.26.0904 General Hospital of Larissa
  • 1160.26.0913 University Hospital of Larissa
  • 1160.26.0912 General Hospital of Leivadia
  • 1160.26.0902 General Hospital " Papageorgiou"
  • 1160.26.0910 General Hospital of Thiva
  • 1160.26.0903 General Hospital of Trikala
  • 1160.26.0905 Boehringer Ingelheim Investigational Site
  • 1160.26.1001 Boehringer Ingelheim Investigational Site
  • 1160.26.1002 Boehringer Ingelheim Investigational Site
  • 1160.26.1003 Boehringer Ingelheim Investigational Site
  • 1160.26.1004 Boehringer Ingelheim Investigational Site
  • 1160.26.1011 Boehringer Ingelheim Investigational Site
  • 1160.26.1012 Boehringer Ingelheim Investigational Site
  • 1160.26.1013 Boehringer Ingelheim Investigational Site
  • 1160.26.1014 Boehringer Ingelheim Investigational Site
  • 1160.26.1015 Boehringer Ingelheim Investigational Site
  • 1160.26.1016 Boehringer Ingelheim Investigational Site
  • 1160.26.1020 Boehringer Ingelheim Investigational Site
  • 1160.26.1017 Boehringer Ingelheim Investigational Site
  • 1160.26.1018 Boehringer Ingelheim Investigational Site
  • 1160.26.1019 Boehringer Ingelheim Investigational Site
  • 1160.26.1056 Boehringer Ingelheim Investigational Site
  • 1160.26.1057 Boehringer Ingelheim Investigational Site
  • 1160.26.1064 Boehringer Ingelheim Investigational Site
  • 1160.26.1065 Boehringer Ingelheim Investigational Site
  • 1160.26.1071 Boehringer Ingelheim Investigational Site
  • 1160.26.1066 Boehringer Ingelheim Investigational Site
  • 1160.26.1069 Boehringer Ingelheim Investigational Site
  • 1160.26.1062 Boehringer Ingelheim Investigational Site
  • 1160.26.1058 Boehringer Ingelheim Investigational Site
  • 1160.26.1053 Boehringer Ingelheim Investigational Site
  • 1160.26.1073 Boehringer Ingelheim Investigational Site
  • 1160.26.1067 Boehringer Ingelheim Investigational Site
  • 1160.26.1068 Boehringer Ingelheim Investigational Site
  • 1160.26.1055 Boehringer Ingelheim Investigational Site
  • 1160.26.1051 Boehringer Ingelheim Investigational Site
  • 1160.26.1060 Boehringer Ingelheim Investigational Site
  • 1160.26.1072 Boehringer Ingelheim Investigational Site
  • 1160.26.1059 Boehringer Ingelheim Investigational Site
  • 1160.26.1052 Boehringer Ingelheim Investigational Site
  • 1160.26.1070 Boehringer Ingelheim Investigational Site
  • 1160.26.1110 Boehringer Ingelheim Investigational Site
  • 1160.26.1121 Boehringer Ingelheim Investigational Site
  • 1160.26.1111 Boehringer Ingelheim Investigational Site
  • 1160.26.1102 Boehringer Ingelheim Investigational Site
  • 1160.26.1117 Boehringer Ingelheim Investigational Site
  • 1160.26.1112 Boehringer Ingelheim Investigational Site
  • 1160.26.1091 Boehringer Ingelheim Investigational Site
  • 1160.26.1113 Boehringer Ingelheim Investigational Site
  • 1160.26.1114 Boehringer Ingelheim Investigational Site
  • 1160.26.1116 Boehringer Ingelheim Investigational Site
  • 1160.26.1118 Boehringer Ingelheim Investigational Site
  • 1160.26.1105 Boehringer Ingelheim Investigational Site
  • 1160.26.1097 Boehringer Ingelheim Investigational Site
  • 1160.26.1101 Boehringer Ingelheim Investigational Site
  • 1160.26.1104 Boehringer Ingelheim Investigational Site
  • 1160.26.1106 Boehringer Ingelheim Investigational Site
  • 1160.26.1119 Boehringer Ingelheim Investigational Site
  • 1160.26.1115 Boehringer Ingelheim Investigational Site
  • 1160.26.1096 Boehringer Ingelheim Investigational Site
  • 1160.26.1093 Boehringer Ingelheim Investigational Site
  • 1160.26.1094 Boehringer Ingelheim Investigational Site
  • 1160.26.1095 Boehringer Ingelheim Investigational Site
  • 1160.26.1100 Boehringer Ingelheim Investigational Site
  • 1160.26.1103 Boehringer Ingelheim Investigational Site
  • 1160.26.1092 Boehringer Ingelheim Investigational Site
  • 1160.26.1098 Boehringer Ingelheim Investigational Site
  • 1160.26.1107 Boehringer Ingelheim Investigational Site
  • 1160.26.1108 Boehringer Ingelheim Investigational Site
  • 1160.26.1109 Boehringer Ingelheim Investigational Site
  • 1160.26.1120 Boehringer Ingelheim Investigational Site
  • 1160.26.1122 Boehringer Ingelheim Investigational Site
  • 1160.26.1099 Boehringer Ingelheim Investigational Site
  • 1160.26.1169 Boehringer Ingelheim Investigational Site
  • 1160.26.1172 Boehringer Ingelheim Investigational Site
  • 1160.26.1180 Boehringer Ingelheim Investigational Site
  • 1160.26.1161 Boehringer Ingelheim Investigational Site
  • 1160.26.1163 Boehringer Ingelheim Investigational Site
  • 1160.26.1178 Boehringer Ingelheim Investigational Site
  • 1160.26.1171 Boehringer Ingelheim Investigational Site
  • 1160.26.1174 Boehringer Ingelheim Investigational Site
  • 1160.26.1167 Boehringer Ingelheim Investigational Site
  • 1160.26.1168 Boehringer Ingelheim Investigational Site
  • 1160.26.1162 Boehringer Ingelheim Investigational Site
  • 1160.26.1177 Boehringer Ingelheim Investigational Site
  • 1160.26.1165 Boehringer Ingelheim Investigational Site
  • 1160.26.1175 Boehringer Ingelheim Investigational Site
  • 1160.26.1181 Boehringer Ingelheim Investigational Site
  • 1160.26.1173 Boehringer Ingelheim Investigational Site
  • 1160.26.1170 Boehringer Ingelheim Investigational Site
  • 1160.26.1176 Boehringer Ingelheim Investigational Site
  • 1160.26.1204 Boehringer Ingelheim Investigational Site
  • 1160.26.1209 Boehringer Ingelheim Investigational Site
  • 1160.26.1193 Boehringer Ingelheim Investigational Site
  • 1160.26.1211 Boehringer Ingelheim Investigational Site
  • 1160.26.1225 Boehringer Ingelheim Investigational Site
  • 1160.26.1221 Boehringer Ingelheim Investigational Site
  • 1160.26.1219 Boehringer Ingelheim Investigational Site
  • 1160.26.1229 Boehringer Ingelheim Investigational Site
  • 1160.26.1232 Boehringer Ingelheim Investigational Site
  • 1160.26.1228 Boehringer Ingelheim Investigational Site
  • 1160.26.1208 Boehringer Ingelheim Investigational Site
  • 1160.26.1214 Boehringer Ingelheim Investigational Site
  • 1160.26.1240 Boehringer Ingelheim Investigational Site
  • 1160.26.1224 Boehringer Ingelheim Investigational Site
  • 1160.26.1194 Boehringer Ingelheim Investigational Site
  • 1160.26.1241 Boehringer Ingelheim Investigational Site
  • 1160.26.1220 Boehringer Ingelheim Investigational Site
  • 1160.26.1203 Boehringer Ingelheim Investigational Site
  • 1160.26.1207 Boehringer Ingelheim Investigational Site
  • 1160.26.1231 Boehringer Ingelheim Investigational Site
  • 1160.26.1233 Boehringer Ingelheim Investigational Site
  • 1160.26.1242 Boehringer Ingelheim Investigational Site
  • 1160.26.1210 Boehringer Ingelheim Investigational Site
  • 1160.26.1218 Boehringer Ingelheim Investigational Site
  • 1160.26.1200 Boehringer Ingelheim Investigational Site
  • 1160.26.1201 Boehringer Ingelheim Investigational Site
  • 1160.26.1216 Boehringer Ingelheim Investigational Site
  • 1160.26.1237 Boehringer Ingelheim Investigational Site
  • 1160.26.1223 Boehringer Ingelheim Investigational Site
  • 1160.26.1197 Boehringer Ingelheim Investigational Site
  • 1160.26.1212 Boehringer Ingelheim Investigational Site
  • 1160.26.1230 Boehringer Ingelheim Investigational Site
  • 1160.26.1238 Boehringer Ingelheim Investigational Site
  • 1160.26.1217 Boehringer Ingelheim Investigational Site
  • 1160.26.1196 Boehringer Ingelheim Investigational Site
  • 1160.26.1191 Boehringer Ingelheim Investigational Site
  • 1160.26.1192 Boehringer Ingelheim Investigational Site
  • 1160.26.1206 Boehringer Ingelheim Investigational Site
  • 1160.26.1235 Boehringer Ingelheim Investigational Site
  • 1160.26.1236 Boehringer Ingelheim Investigational Site
  • 1160.26.1205 Boehringer Ingelheim Investigational Site
  • 1160.26.1234 Boehringer Ingelheim Investigational Site
  • 1160.26.1215 Boehringer Ingelheim Investigational Site
  • 1160.26.1198 Boehringer Ingelheim Investigational Site
  • 1160.26.1195 Boehringer Ingelheim Investigational Site
  • 1160.26.1199 Boehringer Ingelheim Investigational Site
  • 1160.26.1222 Boehringer Ingelheim Investigational Site
  • 1160.26.1227 Boehringer Ingelheim Investigational Site
  • 1160.26.1243 Boehringer Ingelheim Investigational Site
  • 1160.26.1585 Boehringer Ingelheim Investigational Site
  • 1160.26.1586 Boehringer Ingelheim Investigational Site
  • 1160.26.1584 Boehringer Ingelheim Investigational Site
  • 1160.26.1591 Boehringer Ingelheim Investigational Site
  • 1160.26.1590 Boehringer Ingelheim Investigational Site
  • 1160.26.1581 Boehringer Ingelheim Investigational Site
  • 1160.26.1582 Boehringer Ingelheim Investigational Site
  • 1160.26.1583 Boehringer Ingelheim Investigational Site
  • 1160.26.1588 Boehringer Ingelheim Investigational Site
  • 1160.26.1589 Boehringer Ingelheim Investigational Site
  • 1160.26.1592 Boehringer Ingelheim Investigational Site
  • 1160.26.1593 Boehringer Ingelheim Investigational Site
  • 1160.26.1297 Boehringer Ingelheim Investigational Site
  • 1160.26.1291 Boehringer Ingelheim Investigational Site
  • 1160.26.1292 Boehringer Ingelheim Investigational Site
  • 1160.26.1294 Boehringer Ingelheim Investigational Site
  • 1160.26.1293 Boehringer Ingelheim Investigational Site
  • 1160.26.1295 Boehringer Ingelheim Investigational Site
  • 1160.26.1296 Boehringer Ingelheim Investigational Site
  • 1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
  • 1160.26.1311 Hospital Mexico-Americano
  • 1160.26.1317 hOSPITAL bERNARDETTE
  • 1160.26.1312 Hospital de Jesus
  • 1160.26.1319 Instituto Nacional de Cardiologia
  • 1160.26.1314 Hospital 1o. de Octubre
  • 1160.26.1313 Hosp. Angeles Centro Medico del Potosi
  • 1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
  • 1160.26.1344 Boehringer Ingelheim Investigational Site
  • 1160.26.1331 Boehringer Ingelheim Investigational Site
  • 1160.26.1336 Boehringer Ingelheim Investigational Site
  • 1160.26.1332 Boehringer Ingelheim Investigational Site
  • 1160.26.1337 Boehringer Ingelheim Investigational Site
  • 1160.26.1349 Boehringer Ingelheim Investigational Site
  • 1160.26.1345 Boehringer Ingelheim Investigational Site
  • 1160.26.1360 Boehringer Ingelheim Investigational Site
  • 1160.26.1348 Boehringer Ingelheim Investigational Site
  • 1160.26.1340 Boehringer Ingelheim Investigational Site
  • 1160.26.1358 Boehringer Ingelheim Investigational Site
  • 1160.26.1338 Boehringer Ingelheim Investigational Site
  • 1160.26.1343 Boehringer Ingelheim Investigational Site
  • 1160.26.1347 Boehringer Ingelheim Investigational Site
  • 1160.26.1333 Boehringer Ingelheim Investigational Site
  • 1160.26.1355 Boehringer Ingelheim Investigational Site
  • 1160.26.1361 Boehringer Ingelheim Investigational Site
  • 1160.26.1339 Boehringer Ingelheim Investigational Site
  • 1160.26.1346 Boehringer Ingelheim Investigational Site
  • 1160.26.1356 Boehringer Ingelheim Investigational Site
  • 1160.26.1359 Boehringer Ingelheim Investigational Site
  • 1160.26.1341 Boehringer Ingelheim Investigational Site
  • 1160.26.1354 Boehringer Ingelheim Investigational Site
  • 1160.26.1351 Boehringer Ingelheim Investigational Site
  • 1160.26.1334 Boehringer Ingelheim Investigational Site
  • 1160.26.1335 Boehringer Ingelheim Investigational Site
  • 1160.26.1353 Boehringer Ingelheim Investigational Site
  • 1160.26.1352 Boehringer Ingelheim Investigational Site
  • 1160.26.1350 Boehringer Ingelheim Investigational Site
  • 1160.26.1342 Boehringer Ingelheim Investigational Site
  • 1160.26.1357 Boehringer Ingelheim Investigational Site
  • 1160.26.1396 Boehringer Ingelheim Investigational Site
  • 1160.26.1393 Boehringer Ingelheim Investigational Site
  • 1160.26.1395 Boehringer Ingelheim Investigational Site
  • 1160.26.1391 Boehringer Ingelheim Investigational Site
  • 1160.26.1392 Boehringer Ingelheim Investigational Site
  • 1160.26.1397 Boehringer Ingelheim Investigational Site
  • 1160.26.1394 Boehringer Ingelheim Investigational Site
  • 1160.26.1415 Hospital Alberto Sabogal
  • 1160.26.1411 Clinica San Felipe
  • 1160.26.1412 Clínica Anglo Americana
  • 1160.26.1413 Hospital Cayetano Heredia
  • 1160.26.1414 Clínica Vesalio
  • 1160.26.1421 Philippine General Hospital
  • 1160.26.1422 Manila Doctors Hospital
  • 1160.26.1424 The Medical City
  • 1160.26.1423 Philippine Heart Center
  • 1160.26.1425 St Lukes Medical Center
  • 1160.26.1437 Boehringer Ingelheim Investigational Site
  • 1160.26.1436 Boehringer Ingelheim Investigational Site
  • 1160.26.1438 Boehringer Ingelheim Investigational Site
  • 1160.26.1435 Boehringer Ingelheim Investigational Site
  • 1160.26.1439 Boehringer Ingelheim Investigational Site
  • 1160.26.1440 Boehringer Ingelheim Investigational Site
  • 1160.26.1433 Boehringer Ingelheim Investigational Site
  • 1160.26.1431 Boehringer Ingelheim Investigational Site
  • 1160.26.1432 Boehringer Ingelheim Investigational Site
  • 1160.26.1434 Boehringer Ingelheim Investigational Site
  • 1160.26.1456 Boehringer Ingelheim Investigational Site
  • 1160.26.1451 Boehringer Ingelheim Investigational Site
  • 1160.26.1454 Boehringer Ingelheim Investigational Site
  • 1160.26.1459 Boehringer Ingelheim Investigational Site
  • 1160.26.1457 Boehringer Ingelheim Investigational Site
  • 1160.26.1453 Boehringer Ingelheim Investigational Site
  • 1160.26.1458 Boehringer Ingelheim Investigational Site
  • 1160.26.1455 Boehringer Ingelheim Investigational Site
  • 1160.26.1452 Boehringer Ingelheim Investigational Site
  • 1160.26.1471 Boehringer Ingelheim Investigational Site
  • 1160.26.1472 Boehringer Ingelheim Investigational Site
  • 1160.26.1478 Boehringer Ingelheim Investigational Site
  • 1160.26.1501 Boehringer Ingelheim Investigational Site
  • 1160.26.1502 Boehringer Ingelheim Investigational Site
  • 1160.26.1503 Boehringer Ingelheim Investigational Site
  • 1160.26.1504 Boehringer Ingelheim Investigational Site
  • 1160.26.1505 Boehringer Ingelheim Investigational Site
  • 1160.26.1506 Boehringer Ingelheim Investigational Site
  • 1160.26.1507 Boehringer Ingelheim Investigational Site
  • 1160.26.1508 Boehringer Ingelheim Investigational Site
  • 1160.26.1509 Boehringer Ingelheim Investigational Site
  • 1160.26.1510 Boehringer Ingelheim Investigational Site
  • 1160.26.1511 Boehringer Ingelheim Investigational Site
  • 1160.26.1512 Boehringer Ingelheim Investigational Site
  • 1160.26.1513 Boehringer Ingelheim Investigational Site
  • 1160.26.1514 Boehringer Ingelheim Investigational Site
  • 1160.26.1515 Boehringer Ingelheim Investigational Site
  • 1160.26.1531 Boehringer Ingelheim Investigational Site
  • 1160.26.1532 Boehringer Ingelheim Investigational Site
  • 1160.26.1548 Boehringer Ingelheim Investigational Site
  • 1160.26.1541 Boehringer Ingelheim Investigational Site
  • 1160.26.1542 Boehringer Ingelheim Investigational Site
  • 1160.26.1543 Boehringer Ingelheim Investigational Site
  • 1160.26.1544 Boehringer Ingelheim Investigational Site
  • 1160.26.1545 Boehringer Ingelheim Investigational Site
  • 1160.26.1546 Boehringer Ingelheim Investigational Site
  • 1160.26.1549 Boehringer Ingelheim Investigational Site
  • 1160.26.1550 Boehringer Ingelheim Investigational Site
  • 1160.26.1547 Boehringer Ingelheim Investigational Site
  • 1160.26.1562 Boehringer Ingelheim Investigational Site
  • 1160.26.1569 Boehringer Ingelheim Investigational Site
  • 1160.26.1561 Boehringer Ingelheim Investigational Site
  • 1160.26.1564 Boehringer Ingelheim Investigational Site
  • 1160.26.1567 Boehringer Ingelheim Investigational Site
  • 1160.26.1568 Boehringer Ingelheim Investigational Site
  • 1160.26.1566 Boehringer Ingelheim Investigational Site
  • 1160.26.1563 Boehringer Ingelheim Investigational Site
  • 1160.26.1565 Boehringer Ingelheim Investigational Site
  • 1160.26.1601 Boehringer Ingelheim Investigational Site
  • 1160.26.1606 Boehringer Ingelheim Investigational Site
  • 1160.26.1607 Boehringer Ingelheim Investigational Site
  • 1160.26.1604 Boehringer Ingelheim Investigational Site
  • 1160.26.1609 Boehringer Ingelheim Investigational Site
  • 1160.26.1603 Boehringer Ingelheim Investigational Site
  • 1160.26.1608 Boehringer Ingelheim Investigational Site
  • 1160.26.1605 Boehringer Ingelheim Investigational Site
  • 1160.26.1602 Boehringer Ingelheim Investigational Site
  • 1160.26.1633 Sahlgrenska Sjukhuset
  • 1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
  • 1160.26.1631 Universitetssjukhuset i Linköping
  • 1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
  • 1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
  • 1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
  • 1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
  • 1160.26.1632 Capio S:t Görans Sjukhus
  • 1160.26.1634 Södersjukhuset
  • 1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
  • 1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
  • 1160.26.1635 UCR/Uppsala
  • 1160.26.1622 Hjärtmottagningen, Centrallasarettet
  • 1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
  • 1160.26.1652 Boehringer Ingelheim Investigational Site
  • 1160.26.1655 Boehringer Ingelheim Investigational Site
  • 1160.26.1651 Boehringer Ingelheim Investigational Site
  • 1160.26.1654 Boehringer Ingelheim Investigational Site
  • 1160.26.1680 Boehringer Ingelheim Investigational Site
  • 1160.26.1683 Boehringer Ingelheim Investigational Site
  • 1160.26.1682 Boehringer Ingelheim Investigational Site
  • 1160.26.1679 China Medical University Hospital
  • 1160.26.1681 Boehringer Ingelheim Investigational Site
  • 1160.26.1671 Boehringer Ingelheim Investigational Site
  • 1160.26.1672 Boehringer Ingelheim Investigational Site
  • 1160.26.1673 Boehringer Ingelheim Investigational Site
  • 1160.26.1674 Boehringer Ingelheim Investigational Site
  • 1160.26.1675 Boehringer Ingelheim Investigational Site
  • 1160.26.1676 Boehringer Ingelheim Investigational Site
  • 1160.26.1677 Boehringer Ingelheim Investigational Site
  • 1160.26.1678 Boehringer Ingelheim Investigational Site
  • 1160.26.1701 Boehringer Ingelheim Investigational Site
  • 1160.26.1702 Boehringer Ingelheim Investigational Site
  • 1160.26.1703 Boehringer Ingelheim Investigational Site
  • 1160.26.1704 Boehringer Ingelheim Investigational Site
  • 1160.26.1705 Boehringer Ingelheim Investigational Site
  • 1160.26.1715 Boehringer Ingelheim Investigational Site
  • 1160.26.1711 Boehringer Ingelheim Investigational Site
  • 1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
  • 1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
  • 1160.26.1727 Boehringer Ingelheim Investigational Site
  • 1160.26.1726 Boehringer Ingelheim Investigational Site
  • 1160.26.1724 Boehringer Ingelheim Investigational Site
  • 1160.26.1725 Boehringer Ingelheim Investigational Site
  • 1160.26.1721 Boehringer Ingelheim Investigational Site
  • 1160.26.1722 Boehringer Ingelheim Investigational Site
  • 1160.26.1723 Boehringer Ingelheim Investigational Site
  • 1160.26.1728 Boehringer Ingelheim Investigational Site
  • 1160.26.1730 Boehringer Ingelheim Investigational Site
  • 1160.26.1731 Boehringer Ingelheim Investigational Site
  • 1160.26.1729 Boehringer Ingelheim Investigational Site
  • 1160.26.1744 Boehringer Ingelheim Investigational Site
  • 1160.26.1746 Boehringer Ingelheim Investigational Site
  • 1160.26.1747 Boehringer Ingelheim Investigational Site
  • 1160.26.1750 Boehringer Ingelheim Investigational Site
  • 1160.26.1753 Boehringer Ingelheim Investigational Site
  • 1160.26.1755 Boehringer Ingelheim Investigational Site
  • 1160.26.1749 Boehringer Ingelheim Investigational Site
  • 1160.26.1741 Boehringer Ingelheim Investigational Site
  • 1160.26.1756 Boehringer Ingelheim Investigational Site
  • 1160.26.1742 Boehringer Ingelheim Investigational Site
  • 1160.26.1751 Boehringer Ingelheim Investigational Site
  • 1160.26.1752 Boehringer Ingelheim Investigational Site
  • 1160.26.1745 Boehringer Ingelheim Investigational Site
  • 1160.26.1743 Boehringer Ingelheim Investigational Site
  • 1160.26.1754 Boehringer Ingelheim Investigational Site
  • 1160.26.1748 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Dabigatran dose 2

Warfarin

Dabigatran dose 1

Arm Description

twice a day

once a day

twice a day

Outcomes

Primary Outcome Measures

Yearly Event Rate for Composite Endpoint of Stroke/SEE
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

Secondary Outcome Measures

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Bleeding Events (Major and Minor)
Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)
Abnormal Liver Function Test
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN

Full Information

First Posted
December 6, 2005
Last Updated
April 8, 2019
Sponsor
Boehringer Ingelheim
Collaborators
Population Health Research Institute, Uppsala University
search

1. Study Identification

Unique Protocol Identification Number
NCT00262600
Brief Title
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Official Title
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
December 2005 (Actual)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim
Collaborators
Population Health Research Institute, Uppsala University

4. Oversight

5. Study Description

Brief Summary
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Stroke

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Allocation
Randomized
Enrollment
18113 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dabigatran dose 2
Arm Type
Active Comparator
Arm Description
twice a day
Arm Title
Warfarin
Arm Type
Active Comparator
Arm Description
once a day
Arm Title
Dabigatran dose 1
Arm Type
Active Comparator
Arm Description
twice a day
Intervention Type
Drug
Intervention Name(s)
warfarin
Intervention Description
once a day
Intervention Type
Drug
Intervention Name(s)
Dabigatran dose 1
Intervention Description
twice daily
Intervention Type
Drug
Intervention Name(s)
Dabigatran dose 2
Intervention Description
twice a day
Primary Outcome Measure Information:
Title
Yearly Event Rate for Composite Endpoint of Stroke/SEE
Description
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time Frame
36 months
Secondary Outcome Measure Information:
Title
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
Description
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time Frame
36 months
Title
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
Description
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Time Frame
36 months
Title
Bleeding Events (Major and Minor)
Description
Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.
Time Frame
36 months
Title
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
Description
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)
Time Frame
36 months
Title
Abnormal Liver Function Test
Description
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, TIA, or systemic embolism, left ventricular dysfunction, age >=75 years, age >=65 with either diabetes mellitus, history of coronary artery disease or hypertension) Exclusion criteria Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days Conditions associated with an increased risk of bleeding Contraindication to warfarin treatment Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). Plan to perform a pulmonary vein ablation or surgery for cure of the AF Severe renal impairment (estimated creatinine clearance <=30 mL/min) Active infective endocarditis Active liver disease Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study Anaemia (haemoglobin <100g/L) or thrombocytopenia (platelet count <100 x 109/L) Patients who have developed transaminase elevations upon exposure to ximelagatran Patients who have received an investigational drug in the past 30 days or are participating in another drug study Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse) Any known hypersensitivity to galactose if the warfarin used contains galactose.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1160.26.0009 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.26.0046 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.26.0057 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.26.0211 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.26.0206 Boehringer Ingelheim Investigational Site
City
Huntsville
State/Province
Alabama
Country
United States
Facility Name
1160.26.0115 Boehringer Ingelheim Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
1160.26.0104 Boehringer Ingelheim Investigational Site
City
Lake Havasu City
State/Province
Arizona
Country
United States
Facility Name
1160.26.0304 Boehringer Ingelheim Investigational Site
City
Peoria
State/Province
Arizona
Country
United States
Facility Name
1160.26.0185 Boehringer Ingelheim Investigational Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
1160.26.0305 Boehringer Ingelheim Investigational Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
1160.26.0038 Boehringer Ingelheim Investigational Site
City
Hot Springs
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0302 Boehringer Ingelheim Investigational Site
City
Jonesboro
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0121 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0191 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0204 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0213 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0455 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.26.0388 Boehringer Ingelheim Investigational Site
City
Anaheim
State/Province
California
Country
United States
Facility Name
1160.26.0441 Boehringer Ingelheim Investigational Site
City
Carmichael
State/Province
California
Country
United States
Facility Name
1160.26.0145 Boehringer Ingelheim Investigational Site
City
French Camp
State/Province
California
Country
United States
Facility Name
1160.26.0333 Boehringer Ingelheim Investigational Site
City
Fullerton
State/Province
California
Country
United States
Facility Name
1160.26.0384 Boehringer Ingelheim Investigational Site
City
La Jolla
State/Province
California
Country
United States
Facility Name
1160.26.0091 Boehringer Ingelheim Investigational Site
City
La Mesa
State/Province
California
Country
United States
Facility Name
1160.26.0246 Boehringer Ingelheim Investigational Site
City
Lancaster
State/Province
California
Country
United States
Facility Name
1160.26.0345 Boehringer Ingelheim Investigational Site
City
Larkspur
State/Province
California
Country
United States
Facility Name
1160.26.0217 Boehringer Ingelheim Investigational Site
City
Loma Linda
State/Province
California
Country
United States
Facility Name
1160.26.0059 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
1160.26.0088 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
1160.26.0337 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
1160.26.0326 Boehringer Ingelheim Investigational Site
City
Mather
State/Province
California
Country
United States
Facility Name
1160.26.0070 Boehringer Ingelheim Investigational Site
City
Merced
State/Province
California
Country
United States
Facility Name
1160.26.0349 Boehringer Ingelheim Investigational Site
City
Oakland
State/Province
California
Country
United States
Facility Name
1160.26.0016 Boehringer Ingelheim Investigational Site
City
Oceanside
State/Province
California
Country
United States
Facility Name
1160.26.0087 Boehringer Ingelheim Investigational Site
City
Palm Springs
State/Province
California
Country
United States
Facility Name
1160.26.0459 Boehringer Ingelheim Investigational Site
City
Pasadena
State/Province
California
Country
United States
Facility Name
1160.26.0216 Boehringer Ingelheim Investigational Site
City
Redondo Beach
State/Province
California
Country
United States
Facility Name
1160.26.0135 Boehringer Ingelheim Investigational Site
City
Riverside
State/Province
California
Country
United States
Facility Name
1160.26.0162 Boehringer Ingelheim Investigational Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
1160.26.0300 Boehringer Ingelheim Investigational Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
1160.26.0371 Boehringer Ingelheim Investigational Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
1160.26.0116 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1160.26.0148 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1160.26.0270 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1160.26.0284 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1160.26.0351 Boehringer Ingelheim Investigational Site
City
Santa Ana
State/Province
California
Country
United States
Facility Name
1160.26.0043 Boehringer Ingelheim Investigational Site
City
Santa Rosa
State/Province
California
Country
United States
Facility Name
1160.26.0462 Boehringer Ingelheim Investigational Site
City
Sylmar
State/Province
California
Country
United States
Facility Name
1160.26.0276 Boehringer Ingelheim Investigational Site
City
Torrance
State/Province
California
Country
United States
Facility Name
1160.26.0379 Boehringer Ingelheim Investigational Site
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
1160.26.0419 Boehringer Ingelheim Investigational Site
City
Aurora
State/Province
Colorado
Country
United States
Facility Name
1160.26.0321 Boehringer Ingelheim Investigational Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
1160.26.0449 Boehringer Ingelheim Investigational Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
1160.26.0360 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1160.26.0413 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1160.26.0362 Boehringer Ingelheim Investigational Site
City
Fort Collins
State/Province
Colorado
Country
United States
Facility Name
1160.26.0399 Boehringer Ingelheim Investigational Site
City
Greeley
State/Province
Colorado
Country
United States
Facility Name
1160.26.0058 Boehringer Ingelheim Investigational Site
City
Bridgeport
State/Province
Connecticut
Country
United States
Facility Name
1160.26.0241 Boehringer Ingelheim Investigational Site
City
Bridgeport
State/Province
Connecticut
Country
United States
Facility Name
1160.26.0278 Boehringer Ingelheim Investigational Site
City
Bridgeport
State/Province
Connecticut
Country
United States
Facility Name
1160.26.0085 Boehringer Ingelheim Investigational Site
City
Fairfield
State/Province
Connecticut
Country
United States
Facility Name
1160.26.0482 Boehringer Ingelheim Investigational Site
City
Guilford
State/Province
Connecticut
Country
United States
Facility Name
1160.26.0366 Boehringer Ingelheim Investigational Site
City
Newark
State/Province
Delaware
Country
United States
Facility Name
1160.26.0343 Boehringer Ingelheim Investigational Site
City
Washington
State/Province
District of Columbia
Country
United States
Facility Name
1160.26.0022 Boehringer Ingelheim Investigational Site
City
Atlantis
State/Province
Florida
Country
United States
Facility Name
1160.26.0382 Boehringer Ingelheim Investigational Site
City
Boynton Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0056 Boehringer Ingelheim Investigational Site
City
Brandon
State/Province
Florida
Country
United States
Facility Name
1160.26.0105 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
1160.26.0296 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
1160.26.0429 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
1160.26.0376 Boehringer Ingelheim Investigational Site
City
Daytona Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0411 Boehringer Ingelheim Investigational Site
City
Deerfield Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0074 Boehringer Ingelheim Investigational Site
City
Fort Myers
State/Province
Florida
Country
United States
Facility Name
1160.26.0239 Boehringer Ingelheim Investigational Site
City
Gainesville
State/Province
Florida
Country
United States
Facility Name
1160.26.0260 Boehringer Ingelheim Investigational Site
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
1160.26.0265 Boehringer Ingelheim Investigational Site
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
1160.26.0100 Boehringer Ingelheim Investigational Site
City
Inverness
State/Province
Florida
Country
United States
Facility Name
1160.26.0209 Boehringer Ingelheim Investigational Site
City
Jacksonville Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0033 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0089 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0232 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0240 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0427 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0464 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.26.0012 Boehringer Ingelheim Investigational Site
City
Lakeland
State/Province
Florida
Country
United States
Facility Name
1160.26.0259 Boehringer Ingelheim Investigational Site
City
Melbourne
State/Province
Florida
Country
United States
Facility Name
1160.26.0358 Boehringer Ingelheim Investigational Site
City
Melbourne
State/Province
Florida
Country
United States
Facility Name
1160.26.0034 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1160.26.0199 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1160.26.0227 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1160.26.0095 Boehringer Ingelheim Investigational Site
City
Ormond Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0037 Boehringer Ingelheim Investigational Site
City
Pensacola
State/Province
Florida
Country
United States
Facility Name
1160.26.0076 Boehringer Ingelheim Investigational Site
City
Pensacola
State/Province
Florida
Country
United States
Facility Name
1160.26.0081 Boehringer Ingelheim Investigational Site
City
Pensacola
State/Province
Florida
Country
United States
Facility Name
1160.26.0111 Boehringer Ingelheim Investigational Site
City
Pensacola
State/Province
Florida
Country
United States
Facility Name
1160.26.0137 Boehringer Ingelheim Investigational Site
City
Port Charlotte
State/Province
Florida
Country
United States
Facility Name
1160.26.0389 Boehringer Ingelheim Investigational Site
City
Port Charlotte
State/Province
Florida
Country
United States
Facility Name
1160.26.0417 Boehringer Ingelheim Investigational Site
City
Port Charlotte
State/Province
Florida
Country
United States
Facility Name
1160.26.0332 Boehringer Ingelheim Investigational Site
City
Rockledge
State/Province
Florida
Country
United States
Facility Name
1160.26.0226 Boehringer Ingelheim Investigational Site
City
Safety Harbor
State/Province
Florida
Country
United States
Facility Name
1160.26.0015 Boehringer Ingelheim Investigational Site
City
Saint Petersburg
State/Province
Florida
Country
United States
Facility Name
1160.26.0339 Boehringer Ingelheim Investigational Site
City
Saint Petersburg
State/Province
Florida
Country
United States
Facility Name
1160.26.0031 Boehringer Ingelheim Investigational Site
City
Sarasota
State/Province
Florida
Country
United States
Facility Name
1160.26.0385 Boehringer Ingelheim Investigational Site
City
Sarasota
State/Province
Florida
Country
United States
Facility Name
1160.26.0010 Boehringer Ingelheim Investigational Site
City
Stuart
State/Province
Florida
Country
United States
Facility Name
1160.26.0327 Boehringer Ingelheim Investigational Site
City
Tamarac
State/Province
Florida
Country
United States
Facility Name
1160.26.0271 Boehringer Ingelheim Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
1160.26.0328 Boehringer Ingelheim Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
1160.26.0381 Boehringer Ingelheim Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
1160.26.0019 Boehringer Ingelheim Investigational Site
City
Vero Beach
State/Province
Florida
Country
United States
Facility Name
1160.26.0159 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
1160.26.0283 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
1160.26.0338 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
1160.26.0021 Boehringer Ingelheim Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
1160.26.0319 Boehringer Ingelheim Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
1160.26.0092 Boehringer Ingelheim Investigational Site
City
Blue Ridge
State/Province
Georgia
Country
United States
Facility Name
1160.26.0161 Boehringer Ingelheim Investigational Site
City
Conyers
State/Province
Georgia
Country
United States
Facility Name
1160.26.0026 Boehringer Ingelheim Investigational Site
City
Coeur d'Alene
State/Province
Idaho
Country
United States
Facility Name
1160.26.0218 Boehringer Ingelheim Investigational Site
City
Berwyn
State/Province
Illinois
Country
United States
Facility Name
1160.26.0184 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.26.0233 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.26.0324 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.26.0457 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.26.0237 Boehringer Ingelheim Investigational Site
City
Evanston
State/Province
Illinois
Country
United States
Facility Name
1160.26.0236 Boehringer Ingelheim Investigational Site
City
Glenview
State/Province
Illinois
Country
United States
Facility Name
1160.26.0396 Boehringer Ingelheim Investigational Site
City
Hines
State/Province
Illinois
Country
United States
Facility Name
1160.26.0438 Boehringer Ingelheim Investigational Site
City
Maywood
State/Province
Illinois
Country
United States
Facility Name
1160.26.0331 Boehringer Ingelheim Investigational Site
City
Melrose Park
State/Province
Illinois
Country
United States
Facility Name
1160.26.0364 Boehringer Ingelheim Investigational Site
City
Normal
State/Province
Illinois
Country
United States
Facility Name
1160.26.0109 Boehringer Ingelheim Investigational Site
City
North Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.26.0152 Boehringer Ingelheim Investigational Site
City
Oak Lawn
State/Province
Illinois
Country
United States
Facility Name
1160.26.0198 Boehringer Ingelheim Investigational Site
City
Rockford
State/Province
Illinois
Country
United States
Facility Name
1160.26.0433 Boehringer Ingelheim Investigational Site
City
Winfield
State/Province
Illinois
Country
United States
Facility Name
1160.26.0041 Boehringer Ingelheim Investigational Site
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
1160.26.0377 Boehringer Ingelheim Investigational Site
City
Fort Wayne
State/Province
Indiana
Country
United States
Facility Name
1160.26.0288 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.26.0352 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.26.0436 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.26.0028 Boehringer Ingelheim Investigational Site
City
Jeffersonville
State/Province
Indiana
Country
United States
Facility Name
1160.26.0235 Boehringer Ingelheim Investigational Site
City
South Bend
State/Province
Indiana
Country
United States
Facility Name
1160.26.0268 Boehringer Ingelheim Investigational Site
City
Dubuque
State/Province
Iowa
Country
United States
Facility Name
1160.26.0001 Boehringer Ingelheim Investigational Site
City
West Des Moines
State/Province
Iowa
Country
United States
Facility Name
1160.26.0189 Boehringer Ingelheim Investigational Site
City
West Des Moines
State/Province
Iowa
Country
United States
Facility Name
1160.26.0357 Boehringer Ingelheim Investigational Site
City
West Des Moines
State/Province
Iowa
Country
United States
Facility Name
1160.26.0354 Boehringer Ingelheim Investigational Site
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
1160.26.0077 Boehringer Ingelheim Investigational Site
City
Bowling Green
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0138 Boehringer Ingelheim Investigational Site
City
Crestview Hills
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0422 Boehringer Ingelheim Investigational Site
City
Lexington
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0178 Boehringer Ingelheim Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0397 Boehringer Ingelheim Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0310 Boehringer Ingelheim Investigational Site
City
Owensboro
State/Province
Kentucky
Country
United States
Facility Name
1160.26.0011 Boehringer Ingelheim Investigational Site
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0144 Boehringer Ingelheim Investigational Site
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0404 Boehringer Ingelheim Investigational Site
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0093 Boehringer Ingelheim Investigational Site
City
Covington
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0340 Boehringer Ingelheim Investigational Site
City
Lacombe
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0018 Boehringer Ingelheim Investigational Site
City
Lafayette
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0391 Boehringer Ingelheim Investigational Site
City
Lafayette
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0252 Boehringer Ingelheim Investigational Site
City
Morgan City
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0132 Boehringer Ingelheim Investigational Site
City
New Iberia
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0299 Tulane University School Of Medicine
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0048 Boehringer Ingelheim Investigational Site
City
Shreveport
State/Province
Louisiana
Country
United States
Facility Name
1160.26.0096 Boehringer Ingelheim Investigational Site
City
Auburn
State/Province
Maine
Country
United States
Facility Name
1160.26.0068 Boehringer Ingelheim Investigational Site
City
Scarborough
State/Province
Maine
Country
United States
Facility Name
1160.26.0114 Boehringer Ingelheim Investigational Site
City
Annapolis
State/Province
Maryland
Country
United States
Facility Name
1160.26.0164 Boehringer Ingelheim Investigational Site
City
Annapolis
State/Province
Maryland
Country
United States
Facility Name
1160.26.0023 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.26.0047 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.26.0079 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.26.0186 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.26.0194 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.26.0255 Boehringer Ingelheim Investigational Site
City
Bel Air
State/Province
Maryland
Country
United States
Facility Name
1160.26.0398 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Maryland
Country
United States
Facility Name
1160.26.0177 Boehringer Ingelheim Investigational Site
City
Rockville
State/Province
Maryland
Country
United States
Facility Name
1160.26.0073 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
Maryland
Country
United States
Facility Name
1160.26.0207 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
Maryland
Country
United States
Facility Name
1160.26.0196 Boehringer Ingelheim Investigational Site
City
Takoma Park
State/Province
Maryland
Country
United States
Facility Name
1160.26.0187 Boehringer Ingelheim Investigational Site
City
Towson
State/Province
Maryland
Country
United States
Facility Name
1160.26.0052 Boehringer Ingelheim Investigational Site
City
Westminster
State/Province
Maryland
Country
United States
Facility Name
1160.26.0042 Boehringer Ingelheim Investigational Site
City
Ayer
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0401 Boehringer Ingelheim Investigational Site
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0160 Boehringer Ingelheim Investigational Site
City
East Bridgewater
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0443 Boehringer Ingelheim Investigational Site
City
Haverhill
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0452 Boehringer Ingelheim Investigational Site
City
Haverhill
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0029 Boehringer Ingelheim Investigational Site
City
Natick
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0446 Boehringer Ingelheim Investigational Site
City
Newtown
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0003 Boehringer Ingelheim Investigational Site
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0470 Boehringer Ingelheim Investigational Site
City
Northborough
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0308 Boehringer Ingelheim Investigational Site
City
Worcester
State/Province
Massachusetts
Country
United States
Facility Name
1160.26.0141 Boehringer Ingelheim Investigational Site
City
Bloomfield Hills
State/Province
Michigan
Country
United States
Facility Name
1160.26.0225 Boehringer Ingelheim Investigational Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
1160.26.0154 Boehringer Ingelheim Investigational Site
City
Grand Blanc
State/Province
Michigan
Country
United States
Facility Name
1160.26.0030 Boehringer Ingelheim Investigational Site
City
Grand Rapids
State/Province
Michigan
Country
United States
Facility Name
1160.26.0171 Boehringer Ingelheim Investigational Site
City
Kalamazoo
State/Province
Michigan
Country
United States
Facility Name
1160.26.0205 Boehringer Ingelheim Investigational Site
City
Lapeer
State/Province
Michigan
Country
United States
Facility Name
1160.26.0279 Boehringer Ingelheim Investigational Site
City
Muskegon
State/Province
Michigan
Country
United States
Facility Name
1160.26.0445 Boehringer Ingelheim Investigational Site
City
Petoskey
State/Province
Michigan
Country
United States
Facility Name
1160.26.0274 Boehringer Ingelheim Investigational Site
City
Rochester Hills
State/Province
Michigan
Country
United States
Facility Name
1160.26.0165 Boehringer Ingelheim Investigational Site
City
Saginaw
State/Province
Michigan
Country
United States
Facility Name
1160.26.0020 Boehringer Ingelheim Investigational Site
City
Troy
State/Province
Michigan
Country
United States
Facility Name
1160.26.0188 Boehringer Ingelheim Investigational Site
City
Ypsilanti
State/Province
Michigan
Country
United States
Facility Name
1160.26.0131 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
1160.26.0421 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
1160.26.0202 Boehringer Ingelheim Investigational Site
City
Robbinsdale
State/Province
Minnesota
Country
United States
Facility Name
1160.26.0101 Boehringer Ingelheim Investigational Site
City
Saint Paul
State/Province
Minnesota
Country
United States
Facility Name
1160.26.0086 Boehringer Ingelheim Investigational Site
City
Gulfport
State/Province
Mississippi
Country
United States
Facility Name
1160.26.0119 Boehringer Ingelheim Investigational Site
City
Tupelo
State/Province
Mississippi
Country
United States
Facility Name
1160.26.0055 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Missouri
Country
United States
Facility Name
1160.26.0172 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Missouri
Country
United States
Facility Name
1160.26.0257 Boehringer Ingelheim Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
1160.26.0266 Boehringer Ingelheim Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
1160.26.0336 Boehringer Ingelheim Investigational Site
City
Saint Charles
State/Province
Missouri
Country
United States
Facility Name
1160.26.0249 Boehringer Ingelheim Investigational Site
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
1160.26.0027 Boehringer Ingelheim Investigational Site
City
Kalispell
State/Province
Montana
Country
United States
Facility Name
1160.26.0128 Boehringer Ingelheim Investigational Site
City
Alliance
State/Province
Nebraska
Country
United States
Facility Name
1160.26.0110 Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
1160.26.0355 Boehringer Ingelheim Investigational Site
City
Papillion
State/Province
Nebraska
Country
United States
Facility Name
1160.26.0346 Boehringer Ingelheim Investigational Site
City
Henderson
State/Province
Nevada
Country
United States
Facility Name
1160.26.0066 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1160.26.0174 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1160.26.0430 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1160.26.0190 Boehringer Ingelheim Investigational Site
City
Lebanon
State/Province
New Hampshire
Country
United States
Facility Name
1160.26.0142 Boehringer Ingelheim Investigational Site
City
Browns Mills
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0125 Boehringer Ingelheim Investigational Site
City
Cherry Hill
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0432 Boehringer Ingelheim Investigational Site
City
Elmer
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0448 Boehringer Ingelheim Investigational Site
City
Englewood
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0248 Boehringer Ingelheim Investigational Site
City
Flemington
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0244 Boehringer Ingelheim Investigational Site
City
Haddon Heights
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0243 Boehringer Ingelheim Investigational Site
City
New Brunswick
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0478 Boehringer Ingelheim Investigational Site
City
Oakland
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0392 Boehringer Ingelheim Investigational Site
City
Ocean City
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0472 Boehringer Ingelheim Investigational Site
City
Paterson
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0221 Boehringer Ingelheim Investigational Site
City
Voorhees
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0254 Boehringer Ingelheim Investigational Site
City
Westwood
State/Province
New Jersey
Country
United States
Facility Name
1160.26.0127 Boehringer Ingelheim Investigational Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
1160.26.0423 Boehringer Ingelheim Investigational Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
1160.26.0476 Boehringer Ingelheim Investigational Site
City
Albany
State/Province
New York
Country
United States
Facility Name
1160.26.0113 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
1160.26.0281 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
1160.26.0063 Boehringer Ingelheim Investigational Site
City
Buffalo
State/Province
New York
Country
United States
Facility Name
1160.26.0044 Boehringer Ingelheim Investigational Site
City
Cortlandt Manor
State/Province
New York
Country
United States
Facility Name
1160.26.0373 Boehringer Ingelheim Investigational Site
City
Flushing
State/Province
New York
Country
United States
Facility Name
1160.26.0045 Boehringer Ingelheim Investigational Site
City
Garden City
State/Province
New York
Country
United States
Facility Name
1160.26.0251 Boehringer Ingelheim Investigational Site
City
Kingston
State/Province
New York
Country
United States
Facility Name
1160.26.0229 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
1160.26.0451 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
1160.26.0090 Boehringer Ingelheim Investigational Site
City
New Hyde Park
State/Province
New York
Country
United States
Facility Name
1160.26.0183 Boehringer Ingelheim Investigational Site
City
New Rochelle
State/Province
New York
Country
United States
Facility Name
1160.26.0316 Boehringer Ingelheim Investigational Site
City
New York
State/Province
New York
Country
United States
Facility Name
1160.26.0146 Boehringer Ingelheim Investigational Site
City
North Massapequa
State/Province
New York
Country
United States
Facility Name
1160.26.0210 Boehringer Ingelheim Investigational Site
City
Northport
State/Province
New York
Country
United States
Facility Name
1160.26.0075 Boehringer Ingelheim Investigational Site
City
Poughkeepsie
State/Province
New York
Country
United States
Facility Name
1160.26.0197 Boehringer Ingelheim Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
1160.26.0320 Boehringer Ingelheim Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
1160.26.0064 Boehringer Ingelheim Investigational Site
City
Scarsdale
State/Province
New York
Country
United States
Facility Name
1160.26.0414 Boehringer Ingelheim Investigational Site
City
Troy
State/Province
New York
Country
United States
Facility Name
1160.26.0356 Boehringer Ingelheim Investigational Site
City
Watertown
State/Province
New York
Country
United States
Facility Name
1160.26.0039 Boehringer Ingelheim Investigational Site
City
Williamsville
State/Province
New York
Country
United States
Facility Name
1160.26.0353 Boehringer Ingelheim Investigational Site
City
Asheville
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0080 Boehringer Ingelheim Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0412 Boehringer Ingelheim Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0350 Boehringer Ingelheim Investigational Site
City
Gastonia
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0322 Boehringer Ingelheim Investigational Site
City
Greensboro
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0173 Boehringer Ingelheim Investigational Site
City
High Point
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0108 Boehringer Ingelheim Investigational Site
City
Lexington
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0006 Boehringer Ingelheim Investigational Site
City
Pinehurst
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0002 Boehringer Ingelheim Investigational Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0069 Boehringer Ingelheim Investigational Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0372 Boehringer Ingelheim Investigational Site
City
Wilmington
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0094 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0425 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
1160.26.0102 Boehringer Ingelheim Investigational Site
City
Grand Forks
State/Province
North Dakota
Country
United States
Facility Name
1160.26.0222 Boehringer Ingelheim Investigational Site
City
Jamestown
State/Province
North Dakota
Country
United States
Facility Name
1160.26.0203 Boehringer Ingelheim Investigational Site
City
Akron
State/Province
Ohio
Country
United States
Facility Name
1160.26.0434 Boehringer Ingelheim Investigational Site
City
Canal Fulton
State/Province
Ohio
Country
United States
Facility Name
1160.26.0083 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.26.0402 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.26.0426 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.26.0479 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.26.0263 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1160.26.0480 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1160.26.0267 Boehringer Ingelheim Investigational Site
City
Columbus
State/Province
Ohio
Country
United States
Facility Name
1160.26.0035 Boehringer Ingelheim Investigational Site
City
Dayton
State/Province
Ohio
Country
United States
Facility Name
1160.26.0150 Boehringer Ingelheim Investigational Site
City
Fairview Park
State/Province
Ohio
Country
United States
Facility Name
1160.26.0201 Boehringer Ingelheim Investigational Site
City
Kettering
State/Province
Ohio
Country
United States
Facility Name
1160.26.0223 Boehringer Ingelheim Investigational Site
City
Lorain
State/Province
Ohio
Country
United States
Facility Name
1160.26.0214 Boehringer Ingelheim Investigational Site
City
Lyndhurst
State/Province
Ohio
Country
United States
Facility Name
1160.26.0275 Boehringer Ingelheim Investigational Site
City
Sandusky
State/Province
Ohio
Country
United States
Facility Name
1160.26.0103 Boehringer Ingelheim Investigational Site
City
Westlake
State/Province
Ohio
Country
United States
Facility Name
1160.26.0155 Boehringer Ingelheim Investigational Site
City
Bartlesville
State/Province
Oklahoma
Country
United States
Facility Name
1160.26.0435 Boehringer Ingelheim Investigational Site
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
1160.26.0139 Boehringer Ingelheim Investigational Site
City
Corvallis
State/Province
Oregon
Country
United States
Facility Name
1160.26.0325 Boehringer Ingelheim Investigational Site
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
1160.26.0078 Boehringer Ingelheim Investigational Site
City
Hillsboro
State/Province
Oregon
Country
United States
Facility Name
1160.26.0245 Boehringer Ingelheim Investigational Site
City
Portland
State/Province
Oregon
Country
United States
Facility Name
1160.26.0133 Boehringer Ingelheim Investigational Site
City
Springfield
State/Province
Oregon
Country
United States
Facility Name
1160.26.0301 Boehringer Ingelheim Investigational Site
City
Allentown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0454 Boehringer Ingelheim Investigational Site
City
Altoona
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0295 Boehringer Ingelheim Investigational Site
City
Camp Hill
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0294 Boehringer Ingelheim Investigational Site
City
Hershey
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0369 Boehringer Ingelheim Investigational Site
City
Jenkintown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0303 Boehringer Ingelheim Investigational Site
City
Jersey Shore
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0431 Boehringer Ingelheim Investigational Site
City
Lancaster
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0168 Boehringer Ingelheim Investigational Site
City
Langhorne
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0293 Boehringer Ingelheim Investigational Site
City
Meadowbrook
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0025 Boehringer Ingelheim Investigational Site
City
Newton
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0394 Boehringer Ingelheim Investigational Site
City
Norristown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0158 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0181 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0416 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0344 Boehringer Ingelheim Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0466 Boehringer Ingelheim Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0208 Boehringer Ingelheim Investigational Site
City
Sellersville
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0465 Boehringer Ingelheim Investigational Site
City
Uniontown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0400 Boehringer Ingelheim Investigational Site
City
Upland
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0032 Boehringer Ingelheim Investigational Site
City
Wynnewood
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0067 Boehringer Ingelheim Investigational Site
City
Wyomissing
State/Province
Pennsylvania
Country
United States
Facility Name
1160.26.0212 Boehringer Ingelheim Investigational Site
City
Pawtucket
State/Province
Rhode Island
Country
United States
Facility Name
1160.26.0007 Boehringer Ingelheim Investigational Site
City
Beaufort
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0383 Boehringer Ingelheim Investigational Site
City
Charleston
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0313 Boehringer Ingelheim Investigational Site
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0450 Boehringer Ingelheim Investigational Site
City
Mount Pleasant
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0166 Boehringer Ingelheim Investigational Site
City
Spartanburg
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0008 Boehringer Ingelheim Investigational Site
City
Summerville
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0468 Boehringer Ingelheim Investigational Site
City
West Columbia
State/Province
South Carolina
Country
United States
Facility Name
1160.26.0348 Boehringer Ingelheim Investigational Site
City
Rapid City
State/Province
South Dakota
Country
United States
Facility Name
1160.26.0084 Boehringer Ingelheim Investigational Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0062 Boehringer Ingelheim Investigational Site
City
Germantown
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0370 Boehringer Ingelheim Investigational Site
City
Johnson City
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0323 Boehringer Ingelheim Investigational Site
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0395 Boehringer Ingelheim Investigational Site
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0474 Boehringer Ingelheim Investigational Site
City
Oak Ridge
State/Province
Tennessee
Country
United States
Facility Name
1160.26.0129 Boehringer Ingelheim Investigational Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
1160.26.0410 Boehringer Ingelheim Investigational Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
1160.26.0156 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1160.26.0315 Boehringer Ingelheim Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
1160.26.0444 Boehringer Ingelheim Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
1160.26.0447 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1160.26.0483 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
1160.26.0335 Boehringer Ingelheim Investigational Site
City
Lubbock
State/Province
Texas
Country
United States
Facility Name
1160.26.0230 Boehringer Ingelheim Investigational Site
City
McKinney
State/Province
Texas
Country
United States
Facility Name
1160.26.0467 Boehringer Ingelheim Investigational Site
City
Plano
State/Province
Texas
Country
United States
Facility Name
1160.26.0013 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1160.26.0269 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1160.26.0307 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1160.26.0285 Boehringer Ingelheim Investigational Site
City
San Marcos
State/Province
Texas
Country
United States
Facility Name
1160.26.0215 Boehringer Ingelheim Investigational Site
City
Tyler
State/Province
Texas
Country
United States
Facility Name
1160.26.0367 Boehringer Ingelheim Investigational Site
City
Tyler
State/Province
Texas
Country
United States
Facility Name
1160.26.0195 Boehringer Ingelheim Investigational Site
City
Arlington
State/Province
Virginia
Country
United States
Facility Name
1160.26.0453 Boehringer Ingelheim Investigational Site
City
Charlottesville
State/Province
Virginia
Country
United States
Facility Name
1160.26.0053 Boehringer Ingelheim Investigational Site
City
Chesapeake
State/Province
Virginia
Country
United States
Facility Name
1160.26.0098 Boehringer Ingelheim Investigational Site
City
Danville
State/Province
Virginia
Country
United States
Facility Name
1160.26.0386 Boehringer Ingelheim Investigational Site
City
Falls Church
State/Province
Virginia
Country
United States
Facility Name
1160.26.0428 Boehringer Ingelheim Investigational Site
City
Fredericksburg
State/Province
Virginia
Country
United States
Facility Name
1160.26.0311 Boehringer Ingelheim Investigational Site
City
Harrisonburg
State/Province
Virginia
Country
United States
Facility Name
1160.26.0292 Boehringer Ingelheim Investigational Site
City
Newport News
State/Province
Virginia
Country
United States
Facility Name
1160.26.0224 Boehringer Ingelheim Investigational Site
City
Norfolk
State/Province
Virginia
Country
United States
Facility Name
1160.26.0220 Boehringer Ingelheim Investigational Site
City
Salem
State/Province
Virginia
Country
United States
Facility Name
1160.26.0317 Boehringer Ingelheim Investigational Site
City
Winchester
State/Province
Virginia
Country
United States
Facility Name
1160.26.0287 Boehringer Ingelheim Investigational Site
City
Bellevue
State/Province
Washington
Country
United States
Facility Name
1160.26.0050 Boehringer Ingelheim Investigational Site
City
Bellingham
State/Province
Washington
Country
United States
Facility Name
1160.26.0040 Boehringer Ingelheim Investigational Site
City
Burien
State/Province
Washington
Country
United States
Facility Name
1160.26.0298 Boehringer Ingelheim Investigational Site
City
Olympia
State/Province
Washington
Country
United States
Facility Name
1160.26.0250 Boehringer Ingelheim Investigational Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
1160.26.0256 Boehringer Ingelheim Investigational Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
1160.26.0024 Boehringer Ingelheim Investigational Site
City
Wenatchee
State/Province
Washington
Country
United States
Facility Name
1160.26.0193 Boehringer Ingelheim Investigational Site
City
Charleston
State/Province
West Virginia
Country
United States
Facility Name
1160.26.0169 Boehringer Ingelheim Investigational Site
City
Clarksburg
State/Province
West Virginia
Country
United States
Facility Name
1160.26.0365 Boehringer Ingelheim Investigational Site
City
Huntington
State/Province
West Virginia
Country
United States
Facility Name
1160.26.0072 Boehringer Ingelheim Investigational Site
City
Elkhorn
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0234 Boehringer Ingelheim Investigational Site
City
Green Bay
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0099 Boehringer Ingelheim Investigational Site
City
Madison
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0242 Boehringer Ingelheim Investigational Site
City
Madison
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0359 Boehringer Ingelheim Investigational Site
City
Marshfield
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0461 Boehringer Ingelheim Investigational Site
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
1160.26.0523 Boehringer Ingelheim Investigational Site
City
Bahía Blanca
Country
Argentina
Facility Name
1160.26.0524 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1160.26.0533 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1160.26.0526 Boehringer Ingelheim Investigational Site
City
Cipolletti
Country
Argentina
Facility Name
1160.26.0529 Boehringer Ingelheim Investigational Site
City
Coronel Suárez
Country
Argentina
Facility Name
1160.26.0531 Boehringer Ingelheim Investigational Site
City
Córdoba
Country
Argentina
Facility Name
1160.26.0530 Boehringer Ingelheim Investigational Site
City
La Plata
Country
Argentina
Facility Name
1160.26.0527 Boehringer Ingelheim Investigational Site
City
Mar del Plata
Country
Argentina
Facility Name
1160.26.0532 Boehringer Ingelheim Investigational Site
City
Mar del Plata
Country
Argentina
Facility Name
1160.26.0525 Boehringer Ingelheim Investigational Site
City
Quilmes
Country
Argentina
Facility Name
1160.26.0521 Boehringer Ingelheim Investigational Site
City
Rosario
Country
Argentina
Facility Name
1160.26.0528 Boehringer Ingelheim Investigational Site
City
Salta
Country
Argentina
Facility Name
1160.26.0522 Boehringer Ingelheim Investigational Site
City
Santa Fe
Country
Argentina
Facility Name
1160.26.0508 Boehringer Ingelheim Investigational Site
City
Coffs Harbour
State/Province
New South Wales
Country
Australia
Facility Name
1160.26.0510 Boehringer Ingelheim Investigational Site
City
Gosford
State/Province
New South Wales
Country
Australia
Facility Name
1160.26.0505 Boehringer Ingelheim Investigational Site
City
Herston
State/Province
Queensland
Country
Australia
Facility Name
1160.26.0506 Boehringer Ingelheim Investigational Site
City
Milton
State/Province
Queensland
Country
Australia
Facility Name
1160.26.0509 Boehringer Ingelheim Investigational Site
City
Ashford
State/Province
South Australia
Country
Australia
Facility Name
1160.26.0507 Boehringer Ingelheim Investigational Site
City
Launceston
State/Province
Tasmania
Country
Australia
Facility Name
1160.26.0504 Boehringer Ingelheim Investigational Site
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
1160.26.0501 Boehringer Ingelheim Investigational Site
City
Geelong
State/Province
Victoria
Country
Australia
Facility Name
1160.26.0502 Boehringer Ingelheim Investigational Site
City
Parkville
State/Province
Victoria
Country
Australia
Facility Name
1160.26.0503 Boehringer Ingelheim Investigational Site
City
Prahran
State/Province
Victoria
Country
Australia
Facility Name
1160.26.0543 Boehringer Ingelheim Investigational Site
City
Graz
Country
Austria
Facility Name
1160.26.0549 Boehringer Ingelheim Investigational Site
City
Linz
Country
Austria
Facility Name
1160.26.0546 Boehringer Ingelheim Investigational Site
City
Wels
Country
Austria
Facility Name
1160.26.0541 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0542 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0544 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0545 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0547 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0548 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.26.0550 Boehringer Ingelheim Investigational Site
City
Wr. Neustadt
Country
Austria
Facility Name
1160.26.0564 Boehringer Ingelheim Investigational Site
City
Aalst
Country
Belgium
Facility Name
1160.26.0573 Boehringer Ingelheim Investigational Site
City
Antwerpen
Country
Belgium
Facility Name
1160.26.0575 Boehringer Ingelheim Investigational Site
City
Antwerpen
Country
Belgium
Facility Name
1160.26.0572 Boehringer Ingelheim Investigational Site
City
Brasschaat
Country
Belgium
Facility Name
1160.26.0577 Boehringer Ingelheim Investigational Site
City
Brugge
Country
Belgium
Facility Name
1160.26.0571 Boehringer Ingelheim Investigational Site
City
Brussels
Country
Belgium
Facility Name
1160.26.0581 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
1160.26.0585 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
1160.26.0586 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
1160.26.0563 Boehringer Ingelheim Investigational Site
City
Edegem
Country
Belgium
Facility Name
1160.26.0578 Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
1160.26.0587 Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
1160.26.0574 Boehringer Ingelheim Investigational Site
City
Gent
Country
Belgium
Facility Name
1160.26.0588 Boehringer Ingelheim Investigational Site
City
Gilly
Country
Belgium
Facility Name
1160.26.0580 Boehringer Ingelheim Investigational Site
City
Haine-St.-Paul
Country
Belgium
Facility Name
1160.26.0568 Boehringer Ingelheim Investigational Site
City
Hasselt
Country
Belgium
Facility Name
1160.26.0569 Boehringer Ingelheim Investigational Site
City
Kortrijk
Country
Belgium
Facility Name
1160.26.0561 Boehringer Ingelheim Investigational Site
City
Leuven
Country
Belgium
Facility Name
1160.26.0579 Boehringer Ingelheim Investigational Site
City
Liège
Country
Belgium
Facility Name
1160.26.0583 Boehringer Ingelheim Investigational Site
City
Liège
Country
Belgium
Facility Name
1160.26.0589 Boehringer Ingelheim Investigational Site
City
Mol
Country
Belgium
Facility Name
1160.26.0567 Boehringer Ingelheim Investigational Site
City
Oostende
Country
Belgium
Facility Name
1160.26.0570 Boehringer Ingelheim Investigational Site
City
Roeselare
Country
Belgium
Facility Name
1160.26.0566 Boehringer Ingelheim Investigational Site
City
Tienen
Country
Belgium
Facility Name
1160.26.0562 Boehringer Ingelheim Investigational Site
City
Turnhout
Country
Belgium
Facility Name
1160.26.550648 Boehringer Ingelheim Investigational Site
City
Belo Horizonte
Country
Brazil
Facility Name
1160.26.550654 Boehringer Ingelheim Investigational Site
City
Blumenau
Country
Brazil
Facility Name
1160.26.550644 Boehringer Ingelheim Investigational Site
City
Campinas
Country
Brazil
Facility Name
1160.26.550650 Boehringer Ingelheim Investigational Site
City
Curitiba
Country
Brazil
Facility Name
1160.26.550651 Boehringer Ingelheim Investigational Site
City
Curitiba
Country
Brazil
Facility Name
1160.26.550653 Boehringer Ingelheim Investigational Site
City
Curitiba
Country
Brazil
Facility Name
1160.26.550652 Boehringer Ingelheim Investigational Site
City
Goiania
Country
Brazil
Facility Name
1160.26.550645 Boehringer Ingelheim Investigational Site
City
Marília
Country
Brazil
Facility Name
1160.26.550646 Boehringer Ingelheim Investigational Site
City
São José do Rio Preto
Country
Brazil
Facility Name
1160.26.550647 Boehringer Ingelheim Investigational Site
City
São José do Rio Preto
Country
Brazil
Facility Name
1160.26.550641 Boehringer Ingelheim Investigational Site
City
São Paulo
Country
Brazil
Facility Name
1160.26.550642 Boehringer Ingelheim Investigational Site
City
São Paulo
Country
Brazil
Facility Name
1160.26.550643 Boehringer Ingelheim Investigational Site
City
São Paulo
Country
Brazil
Facility Name
1160.26.550649 Boehringer Ingelheim Investigational Site
City
Uberaba
Country
Brazil
Facility Name
1160.26.0620 Boehringer Ingelheim Investigational Site
City
Pleven
Country
Bulgaria
Facility Name
1160.26.0611 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0612 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0613 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0614 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0615 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0616 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0617 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0618 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0622 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0623 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0624 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0625 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.26.0626 Boehringer Ingelheim Investigational Site
City
Stara Zagora
Country
Bulgaria
Facility Name
1160.26.0621 Boehringer Ingelheim Investigational Site
City
Varna
Country
Bulgaria
Facility Name
1160.26.0694 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1160.26.0696 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1160.26.0680 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0712 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0706 Boehringer Ingelheim Investigational Site
City
Kelowna
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0725 Boehringer Ingelheim Investigational Site
City
Nanaimo
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0691 Boehringer Ingelheim Investigational Site
City
New Westminster
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0714 Boehringer Ingelheim Investigational Site
City
Victoria
State/Province
British Columbia
Country
Canada
Facility Name
1160.26.0701 Boehringer Ingelheim Investigational Site
City
Portage la Prairie
State/Province
Manitoba
Country
Canada
Facility Name
1160.26.0698 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
1160.26.0707 Boehringer Ingelheim Investigational Site
City
Bay Roberts
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
1160.26.0676 Boehringer Ingelheim Investigational Site
City
Antigonish
State/Province
Nova Scotia
Country
Canada
Facility Name
1160.26.0703 Boehringer Ingelheim Investigational Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
1160.26.0679 Boehringer Ingelheim Investigational Site
City
Ajax
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0677 Boehringer Ingelheim Investigational Site
City
Brampton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0674 Boehringer Ingelheim Investigational Site
City
Burlington
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0702 Boehringer Ingelheim Investigational Site
City
Cambridge
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0720 Boehringer Ingelheim Investigational Site
City
Cambridge
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
City
Etobicoke
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0692 Boehringer Ingelheim Investigational Site
City
Grimsby
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0685 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0697 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0710 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0719 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0721 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0689 Boehringer Ingelheim Investigational Site
City
Kitchener
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0695 Boehringer Ingelheim Investigational Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0708 Boehringer Ingelheim Investigational Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0724 Boehringer Ingelheim Investigational Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0688 Boehringer Ingelheim Investigational Site
City
Newmarket
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0672 Boehringer Ingelheim Investigational Site
City
Oshawa
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0687 Boehringer Ingelheim Investigational Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0723 Boehringer Ingelheim Investigational Site
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0715 Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0690 Boehringer Ingelheim Investigational Site
City
Thunder Bay
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0684 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0718 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0711 Boehringer Ingelheim Investigational Site
City
Waterloo
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0686 Boehringer Ingelheim Investigational Site
City
Windsor
State/Province
Ontario
Country
Canada
Facility Name
1160.26.0693 Boehringer Ingelheim Investigational Site
City
Longueuil
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0681 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0683 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0705 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0709 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0716 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0717 Boehringer Ingelheim Investigational Site
City
Quebec City
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0713 Boehringer Ingelheim Investigational Site
City
Saint George-de-Beauce
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0704 Boehringer Ingelheim Investigational Site
City
Saint Jerome
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0699 Boehringer Ingelheim Investigational Site
City
St. Charles-Borromee
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0675 Boehringer Ingelheim Investigational Site
City
St. Hyacinthe
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0700 Boehringer Ingelheim Investigational Site
City
Ste-Foy
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0682 Boehringer Ingelheim Investigational Site
City
Terrebonne (Lachenaie)
State/Province
Quebec
Country
Canada
Facility Name
1160.26.0673 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1160.26.0678 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1160.26.0771 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0772 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0773 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0774 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0775 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0783 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.26.0784 Boehringer Ingelheim Investigational Site
City
Hangzhou
Country
China
Facility Name
1160.26.0776 Boehringer Ingelheim Investigational Site
City
Harbin
Country
China
Facility Name
1160.26.0778 Boehringer Ingelheim Investigational Site
City
QingDao
Country
China
Facility Name
1160.26.0781 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1160.26.0782 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1160.26.0777 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
1160.26.0780 Boehringer Ingelheim Investigational Site
City
Shijiazhuang
Country
China
Facility Name
1160.26.0801 Boehringer Ingelheim Investigational Site
City
Bogotá
Country
Colombia
Facility Name
1160.26.0802 Boehringer Ingelheim Investigational Site
City
Bogotá
Country
Colombia
Facility Name
1160.26.0803 Boehringer Ingelheim Investigational Site
City
Bogotá
Country
Colombia
Facility Name
1160.26.0815 Boehringer Ingelheim Investigational Site
City
Brno
Country
Czechia
Facility Name
1160.26.0816 Boehringer Ingelheim Investigational Site
City
Brno
Country
Czechia
Facility Name
1160.26.0820 Boehringer Ingelheim Investigational Site
City
Ostrava 1
Country
Czechia
Facility Name
1160.26.0818 Boehringer Ingelheim Investigational Site
City
Pardubice
Country
Czechia
Facility Name
1160.26.0814 Boehringer Ingelheim Investigational Site
City
Plzen-Bory
Country
Czechia
Facility Name
1160.26.0813 Boehringer Ingelheim Investigational Site
City
Pragha 9
Country
Czechia
Facility Name
1160.26.0811 Boehringer Ingelheim Investigational Site
City
Prague 5
Country
Czechia
Facility Name
1160.26.0812 Boehringer Ingelheim Investigational Site
City
Praha 6
Country
Czechia
Facility Name
1160.26.0817 Boehringer Ingelheim Investigational Site
City
Pribram
Country
Czechia
Facility Name
1160.26.0819 Boehringer Ingelheim Investigational Site
City
Usti nad Orlici
Country
Czechia
Facility Name
1160.26.0837 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
1160.26.0835 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1160.26.0838 Boehringer Ingelheim Investigational Site
City
Frederikssund
Country
Denmark
Facility Name
1160.26.0833 Boehringer Ingelheim Investigational Site
City
Helsingør
Country
Denmark
Facility Name
1160.26.0834 Boehringer Ingelheim Investigational Site
City
Herlev
Country
Denmark
Facility Name
1160.26.0841 Boehringer Ingelheim Investigational Site
City
Horsens
Country
Denmark
Facility Name
1160.26.0832 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
1160.26.0840 Boehringer Ingelheim Investigational Site
City
Køge
Country
Denmark
Facility Name
1160.26.0831 Boehringer Ingelheim Investigational Site
City
Odense
Country
Denmark
Facility Name
1160.26.0839 Boehringer Ingelheim Investigational Site
City
Roskilde
Country
Denmark
Facility Name
1160.26.0836 Boehringer Ingelheim Investigational Site
City
Svendborg
Country
Denmark
Facility Name
1160.26.0856 Boehringer Ingelheim Investigational Site
City
Espoo
Country
Finland
Facility Name
1160.26.0851 Boehringer Ingelheim Investigational Site
City
HUS
Country
Finland
Facility Name
1160.26.0859 Boehringer Ingelheim Investigational Site
City
Jyväskylä
Country
Finland
Facility Name
1160.26.0855 Boehringer Ingelheim Investigational Site
City
Kuopio
Country
Finland
Facility Name
1160.26.0857 Boehringer Ingelheim Investigational Site
City
Lappeenranta
Country
Finland
Facility Name
1160.26.0854 Boehringer Ingelheim Investigational Site
City
OYS
Country
Finland
Facility Name
1160.26.0858 Boehringer Ingelheim Investigational Site
City
Pori
Country
Finland
Facility Name
1160.26.0852 Boehringer Ingelheim Investigational Site
City
Tampere
Country
Finland
Facility Name
1160.26.0853 Boehringer Ingelheim Investigational Site
City
Turku
Country
Finland
Facility Name
1160.26.0875A Boehringer Ingelheim Investigational Site
City
ABBEVILLE cedex
Country
France
Facility Name
1160.26.0882A Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882B Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882C Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882D Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882E Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882G Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882H Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882I Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882K Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0882L Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0884A Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.26.0887A Boehringer Ingelheim Investigational Site
City
Cholet
Country
France
Facility Name
1160.26.0889A Boehringer Ingelheim Investigational Site
City
Gap
Country
France
Facility Name
1160.26.0888A Boehringer Ingelheim Investigational Site
City
Grenoble
Country
France
Facility Name
1160.26.0879A Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879B Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879C Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879E Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879F Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879G Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879H Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0879S Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0880A Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0880F Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0880G Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0880J Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0881A Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0881D Boehringer Ingelheim Investigational Site
City
Joue les Tours
Country
France
Facility Name
1160.26.0880B Boehringer Ingelheim Investigational Site
City
Joué les Tours
Country
France
Facility Name
1160.26.0880C Boehringer Ingelheim Investigational Site
City
Joué les Tours
Country
France
Facility Name
1160.26.0880D Boehringer Ingelheim Investigational Site
City
Joué les Tours
Country
France
Facility Name
1160.26.0880E Boehringer Ingelheim Investigational Site
City
Joué les Tours
Country
France
Facility Name
1160.26.0874A Boehringer Ingelheim Investigational Site
City
Langres
Country
France
Facility Name
1160.26.0874B Boehringer Ingelheim Investigational Site
City
Langres
Country
France
Facility Name
1160.26.0871A Boehringer Ingelheim Investigational Site
City
Paris
Country
France
Facility Name
1160.26.0873A Boehringer Ingelheim Investigational Site
City
TOULOUSE cedex
Country
France
Facility Name
1160.26.0886A Boehringer Ingelheim Investigational Site
City
Tourcoing
Country
France
Facility Name
1160.26.0872A Boehringer Ingelheim Investigational Site
City
VALENCIENNES cedex
Country
France
Facility Name
1160.26.0872C Boehringer Ingelheim Investigational Site
City
Valenciennes cedex
Country
France
Facility Name
1160.26.0872B Boehringer Ingelheim Investigational Site
City
Valenciennes
Country
France
Facility Name
1160.26.0932 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.26.0948 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.26.0962 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.26.0940 Boehringer Ingelheim Investigational Site
City
Bochum
Country
Germany
Facility Name
1160.26.0936 Boehringer Ingelheim Investigational Site
City
Coburg
Country
Germany
Facility Name
1160.26.0968 Boehringer Ingelheim Investigational Site
City
Dachau
Country
Germany
Facility Name
1160.26.0972 Boehringer Ingelheim Investigational Site
City
Dortmund
Country
Germany
Facility Name
1160.26.0957 Boehringer Ingelheim Investigational Site
City
Duisburg
Country
Germany
Facility Name
1160.26.0971 Boehringer Ingelheim Investigational Site
City
Erlangen
Country
Germany
Facility Name
1160.26.0965 Boehringer Ingelheim Investigational Site
City
Eschweiler
Country
Germany
Facility Name
1160.26.0934 Boehringer Ingelheim Investigational Site
City
Essen
Country
Germany
Facility Name
1160.26.0931 Boehringer Ingelheim Investigational Site
City
Frankfurt/Main
Country
Germany
Facility Name
1160.26.0943 Boehringer Ingelheim Investigational Site
City
Heidelberg
Country
Germany
Facility Name
1160.26.0955 Boehringer Ingelheim Investigational Site
City
Kassel
Country
Germany
Facility Name
1160.26.0963 Boehringer Ingelheim Investigational Site
City
Köln
Country
Germany
Facility Name
1160.26.0946 Boehringer Ingelheim Investigational Site
City
Lahr
Country
Germany
Facility Name
1160.26.0944 Boehringer Ingelheim Investigational Site
City
Limburg
Country
Germany
Facility Name
1160.26.0951 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1160.26.0933 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.26.0945 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.26.0970 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.26.0947 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1160.26.0952 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1160.26.0941 Boehringer Ingelheim Investigational Site
City
Papenburg
Country
Germany
Facility Name
1160.26.0959 Boehringer Ingelheim Investigational Site
City
Suhl
Country
Germany
Facility Name
1160.26.0937 Boehringer Ingelheim Investigational Site
City
Witten
Country
Germany
Facility Name
1160.26.0966 Boehringer Ingelheim Investigational Site
City
Wuppertal
Country
Germany
Facility Name
1160.26.0908 University Hospital of Alexandroupolis
City
Alexandroupolis
Country
Greece
Facility Name
1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
City
Athens
Country
Greece
Facility Name
1160.26.0906 General Hospital ";Evangelismos"
City
Athens
Country
Greece
Facility Name
1160.26.0907 "Pammakaristos" Hospital of Athens
City
Athens
Country
Greece
Facility Name
1160.26.0915 "Hippokratio" Hospital of Athens
City
Athens
Country
Greece
Facility Name
1160.26.0914 2nd IKA Hospital, Thessaloniki
City
Kalamaria-Thessaloniki
Country
Greece
Facility Name
1160.26.0904 General Hospital of Larissa
City
Larissa
Country
Greece
Facility Name
1160.26.0913 University Hospital of Larissa
City
Larissa
Country
Greece
Facility Name
1160.26.0912 General Hospital of Leivadia
City
Leivadia
Country
Greece
Facility Name
1160.26.0902 General Hospital " Papageorgiou"
City
Thessaloniki
Country
Greece
Facility Name
1160.26.0910 General Hospital of Thiva
City
Thiva
Country
Greece
Facility Name
1160.26.0903 General Hospital of Trikala
City
Trikala
Country
Greece
Facility Name
1160.26.0905 Boehringer Ingelheim Investigational Site
City
Voula - Athens
Country
Greece
Facility Name
1160.26.1001 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
1160.26.1002 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
1160.26.1003 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
1160.26.1004 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
1160.26.1011 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1012 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1013 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1014 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1015 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1016 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.26.1020 Boehringer Ingelheim Investigational Site
City
Gyongyos
Country
Hungary
Facility Name
1160.26.1017 Boehringer Ingelheim Investigational Site
City
Komarom
Country
Hungary
Facility Name
1160.26.1018 Boehringer Ingelheim Investigational Site
City
Pecs
Country
Hungary
Facility Name
1160.26.1019 Boehringer Ingelheim Investigational Site
City
Veszprem
Country
Hungary
Facility Name
1160.26.1056 Boehringer Ingelheim Investigational Site
City
Ahmedabad
Country
India
Facility Name
1160.26.1057 Boehringer Ingelheim Investigational Site
City
Ahmedabad
Country
India
Facility Name
1160.26.1064 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1160.26.1065 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1160.26.1071 Boehringer Ingelheim Investigational Site
City
Bikaner
Country
India
Facility Name
1160.26.1066 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
1160.26.1069 Boehringer Ingelheim Investigational Site
City
Coimbatore
Country
India
Facility Name
1160.26.1062 Boehringer Ingelheim Investigational Site
City
Hyderabad
Country
India
Facility Name
1160.26.1058 Boehringer Ingelheim Investigational Site
City
Indore
Country
India
Facility Name
1160.26.1053 Boehringer Ingelheim Investigational Site
City
Jaipur
Country
India
Facility Name
1160.26.1073 Boehringer Ingelheim Investigational Site
City
Jaipur
Country
India
Facility Name
1160.26.1067 Boehringer Ingelheim Investigational Site
City
Kerala
Country
India
Facility Name
1160.26.1068 Boehringer Ingelheim Investigational Site
City
Kottayam
Country
India
Facility Name
1160.26.1055 Boehringer Ingelheim Investigational Site
City
Lucknow
Country
India
Facility Name
1160.26.1051 Boehringer Ingelheim Investigational Site
City
Ludhiana
Country
India
Facility Name
1160.26.1060 Boehringer Ingelheim Investigational Site
City
Mumbai
Country
India
Facility Name
1160.26.1072 Boehringer Ingelheim Investigational Site
City
Mysore
Country
India
Facility Name
1160.26.1059 Boehringer Ingelheim Investigational Site
City
Nagpur
Country
India
Facility Name
1160.26.1052 Boehringer Ingelheim Investigational Site
City
New Delhi
Country
India
Facility Name
1160.26.1070 Boehringer Ingelheim Investigational Site
City
Pune
Country
India
Facility Name
1160.26.1110 Boehringer Ingelheim Investigational Site
City
Afula
Country
Israel
Facility Name
1160.26.1121 Boehringer Ingelheim Investigational Site
City
Afula
Country
Israel
Facility Name
1160.26.1111 Boehringer Ingelheim Investigational Site
City
Ashkelon
Country
Israel
Facility Name
1160.26.1102 Boehringer Ingelheim Investigational Site
City
Be´er Scheva
Country
Israel
Facility Name
1160.26.1117 Boehringer Ingelheim Investigational Site
City
Givatayim
Country
Israel
Facility Name
1160.26.1112 Boehringer Ingelheim Investigational Site
City
Hadera
Country
Israel
Facility Name
1160.26.1091 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.26.1113 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.26.1114 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.26.1116 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.26.1118 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.26.1105 Boehringer Ingelheim Investigational Site
City
Holon
Country
Israel
Facility Name
1160.26.1097 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.26.1101 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.26.1104 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.26.1106 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.26.1119 Boehringer Ingelheim Investigational Site
City
Kfar Saba
Country
Israel
Facility Name
1160.26.1115 Boehringer Ingelheim Investigational Site
City
Nazareth
Country
Israel
Facility Name
1160.26.1096 Boehringer Ingelheim Investigational Site
City
Petah Tikva
Country
Israel
Facility Name
1160.26.1093 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.26.1094 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.26.1095 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.26.1100 Boehringer Ingelheim Investigational Site
City
Rehovot
Country
Israel
Facility Name
1160.26.1103 Boehringer Ingelheim Investigational Site
City
Safed
Country
Israel
Facility Name
1160.26.1092 Boehringer Ingelheim Investigational Site
City
Tel Hashomer
Country
Israel
Facility Name
1160.26.1098 Boehringer Ingelheim Investigational Site
City
Tel Hashomer
Country
Israel
Facility Name
1160.26.1107 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.26.1108 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.26.1109 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.26.1120 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.26.1122 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.26.1099 Boehringer Ingelheim Investigational Site
City
Zerifin
Country
Israel
Facility Name
1160.26.1169 Boehringer Ingelheim Investigational Site
City
Arezzo
Country
Italy
Facility Name
1160.26.1172 Boehringer Ingelheim Investigational Site
City
Ascoli Piceno
Country
Italy
Facility Name
1160.26.1180 Boehringer Ingelheim Investigational Site
City
Bentivoglio (BO)
Country
Italy
Facility Name
1160.26.1161 Boehringer Ingelheim Investigational Site
City
Bologna
Country
Italy
Facility Name
1160.26.1163 Boehringer Ingelheim Investigational Site
City
Castelnuovo Garfagnana
Country
Italy
Facility Name
1160.26.1178 Boehringer Ingelheim Investigational Site
City
Chieti
Country
Italy
Facility Name
1160.26.1171 Boehringer Ingelheim Investigational Site
City
Colleferro
Country
Italy
Facility Name
1160.26.1174 Boehringer Ingelheim Investigational Site
City
Cremona
Country
Italy
Facility Name
1160.26.1167 Boehringer Ingelheim Investigational Site
City
Eboli
Country
Italy
Facility Name
1160.26.1168 Boehringer Ingelheim Investigational Site
City
Isernia
Country
Italy
Facility Name
1160.26.1162 Boehringer Ingelheim Investigational Site
City
Legnago
Country
Italy
Facility Name
1160.26.1177 Boehringer Ingelheim Investigational Site
City
Mantova
Country
Italy
Facility Name
1160.26.1165 Boehringer Ingelheim Investigational Site
City
Perugia SAN Sisto
Country
Italy
Facility Name
1160.26.1175 Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
1160.26.1181 Boehringer Ingelheim Investigational Site
City
San Bonifacio
Country
Italy
Facility Name
1160.26.1173 Boehringer Ingelheim Investigational Site
City
San Daniele Del Friuli
Country
Italy
Facility Name
1160.26.1170 Boehringer Ingelheim Investigational Site
City
Sassari
Country
Italy
Facility Name
1160.26.1176 Boehringer Ingelheim Investigational Site
City
Sassari
Country
Italy
Facility Name
1160.26.1204 Boehringer Ingelheim Investigational Site
City
Abeno-ku, Osaka, Osaka
Country
Japan
Facility Name
1160.26.1209 Boehringer Ingelheim Investigational Site
City
Aki-gun, Hiroshima
Country
Japan
Facility Name
1160.26.1193 Boehringer Ingelheim Investigational Site
City
Aoba-ku, Sendai, Miyagi
Country
Japan
Facility Name
1160.26.1211 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1160.26.1225 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1160.26.1221 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Kobe, Hyogo
Country
Japan
Facility Name
1160.26.1219 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Osaka, Osaka
Country
Japan
Facility Name
1160.26.1229 Boehringer Ingelheim Investigational Site
City
Fujioka-shi , Gunma-ken
Country
Japan
Facility Name
1160.26.1232 Boehringer Ingelheim Investigational Site
City
Fukushima-shi,Fukushima-ken
Country
Japan
Facility Name
1160.26.1228 Boehringer Ingelheim Investigational Site
City
Higashimatsushimashi, Miyagi-ken
Country
Japan
Facility Name
1160.26.1208 Boehringer Ingelheim Investigational Site
City
Himeji, Hyogo
Country
Japan
Facility Name
1160.26.1214 Boehringer Ingelheim Investigational Site
City
Iida, Nagano
Country
Japan
Facility Name
1160.26.1240 Boehringer Ingelheim Investigational Site
City
Isesaki-shi,Gunma
Country
Japan
Facility Name
1160.26.1224 Boehringer Ingelheim Investigational Site
City
Iwakuni, Yamaguchi
Country
Japan
Facility Name
1160.26.1194 Boehringer Ingelheim Investigational Site
City
Izumi-ku, Sendai, Miyagi
Country
Japan
Facility Name
1160.26.1241 Boehringer Ingelheim Investigational Site
City
Kamigyo-ku, Kyoto
Country
Japan
Facility Name
1160.26.1220 Boehringer Ingelheim Investigational Site
City
Kawachinagano, Osaka
Country
Japan
Facility Name
1160.26.1203 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka, Osaka
Country
Japan
Facility Name
1160.26.1207 Boehringer Ingelheim Investigational Site
City
Kita-ku, Sakai, Osaka
Country
Japan
Facility Name
1160.26.1231 Boehringer Ingelheim Investigational Site
City
Komatsu-shi,Ishikawa -ken
Country
Japan
Facility Name
1160.26.1233 Boehringer Ingelheim Investigational Site
City
Kyoto-shi,Kyoto
Country
Japan
Facility Name
1160.26.1242 Boehringer Ingelheim Investigational Site
City
Matsumoto, Nagano
Country
Japan
Facility Name
1160.26.1210 Boehringer Ingelheim Investigational Site
City
Minami-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1160.26.1218 Boehringer Ingelheim Investigational Site
City
Minato, Tokyo
Country
Japan
Facility Name
1160.26.1200 Boehringer Ingelheim Investigational Site
City
Minato-ku, Nagoya, Aichi
Country
Japan
Facility Name
1160.26.1201 Boehringer Ingelheim Investigational Site
City
Minato-ku, Nagoya, Aichi
Country
Japan
Facility Name
1160.26.1216 Boehringer Ingelheim Investigational Site
City
Narashino, Chiba
Country
Japan
Facility Name
1160.26.1237 Boehringer Ingelheim Investigational Site
City
Nishinomiya-shi,Hyogo
Country
Japan
Facility Name
1160.26.1223 Boehringer Ingelheim Investigational Site
City
Okayama, Okayama
Country
Japan
Facility Name
1160.26.1197 Boehringer Ingelheim Investigational Site
City
Oota, Tokyo
Country
Japan
Facility Name
1160.26.1212 Boehringer Ingelheim Investigational Site
City
Otaru, Hokkaido
Country
Japan
Facility Name
1160.26.1230 Boehringer Ingelheim Investigational Site
City
Sagamihara, Kanagawa-ken
Country
Japan
Facility Name
1160.26.1238 Boehringer Ingelheim Investigational Site
City
Sapporo-shi,Hokkai-do
Country
Japan
Facility Name
1160.26.1217 Boehringer Ingelheim Investigational Site
City
Shibuya, Tokyo
Country
Japan
Facility Name
1160.26.1196 Boehringer Ingelheim Investigational Site
City
Shinjuku, Tokyo
Country
Japan
Facility Name
1160.26.1191 Boehringer Ingelheim Investigational Site
City
Shiroishi-ku, Sapporo, Hokkaido
Country
Japan
Facility Name
1160.26.1192 Boehringer Ingelheim Investigational Site
City
Shiroishi-ku, Sapporo, Hokkaido
Country
Japan
Facility Name
1160.26.1206 Boehringer Ingelheim Investigational Site
City
Suita, Osaka
Country
Japan
Facility Name
1160.26.1235 Boehringer Ingelheim Investigational Site
City
Suita-shi, Osaka
Country
Japan
Facility Name
1160.26.1236 Boehringer Ingelheim Investigational Site
City
Suita-shi, Osaka
Country
Japan
Facility Name
1160.26.1205 Boehringer Ingelheim Investigational Site
City
Sumiyoshi-ku, Osaka, Osaka
Country
Japan
Facility Name
1160.26.1234 Boehringer Ingelheim Investigational Site
City
Takatsuki-shi,Osaka
Country
Japan
Facility Name
1160.26.1215 Boehringer Ingelheim Investigational Site
City
Tokorozawa, Saitama
Country
Japan
Facility Name
1160.26.1198 Boehringer Ingelheim Investigational Site
City
Totsuka-ku, Yokohama, Kanagawa
Country
Japan
Facility Name
1160.26.1195 Boehringer Ingelheim Investigational Site
City
Tsuchiura, Ibaragi
Country
Japan
Facility Name
1160.26.1199 Boehringer Ingelheim Investigational Site
City
Ueda, Nagano
Country
Japan
Facility Name
1160.26.1222 Boehringer Ingelheim Investigational Site
City
Wakayama, Wakayama
Country
Japan
Facility Name
1160.26.1227 Boehringer Ingelheim Investigational Site
City
Yanagawa, Fukuoka
Country
Japan
Facility Name
1160.26.1243 Boehringer Ingelheim Investigational Site
City
Yao, Osaka
Country
Japan
Facility Name
1160.26.1585 Boehringer Ingelheim Investigational Site
City
Busan
Country
Korea, Republic of
Facility Name
1160.26.1586 Boehringer Ingelheim Investigational Site
City
Chungchungnam-Do
Country
Korea, Republic of
Facility Name
1160.26.1584 Boehringer Ingelheim Investigational Site
City
Daegu
Country
Korea, Republic of
Facility Name
1160.26.1591 Boehringer Ingelheim Investigational Site
City
Daegu
Country
Korea, Republic of
Facility Name
1160.26.1590 Boehringer Ingelheim Investigational Site
City
Gwangju
Country
Korea, Republic of
Facility Name
1160.26.1581 Boehringer Ingelheim Investigational Site
City
Incheon
Country
Korea, Republic of
Facility Name
1160.26.1582 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1583 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1588 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1589 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1592 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1593 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.26.1297 Boehringer Ingelheim Investigational Site
City
Kajang,Selangor
Country
Malaysia
Facility Name
1160.26.1291 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
1160.26.1292 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
1160.26.1294 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
1160.26.1293 Boehringer Ingelheim Investigational Site
City
Kuching
Country
Malaysia
Facility Name
1160.26.1295 Boehringer Ingelheim Investigational Site
City
Penang
Country
Malaysia
Facility Name
1160.26.1296 Boehringer Ingelheim Investigational Site
City
Penang
Country
Malaysia
Facility Name
1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
City
Durango
Country
Mexico
Facility Name
1160.26.1311 Hospital Mexico-Americano
City
Guadalajara
Country
Mexico
Facility Name
1160.26.1317 hOSPITAL bERNARDETTE
City
Guadalajara
Country
Mexico
Facility Name
1160.26.1312 Hospital de Jesus
City
Mexico
Country
Mexico
Facility Name
1160.26.1319 Instituto Nacional de Cardiologia
City
Mexico
Country
Mexico
Facility Name
1160.26.1314 Hospital 1o. de Octubre
City
México
Country
Mexico
Facility Name
1160.26.1313 Hosp. Angeles Centro Medico del Potosi
City
San Luis Potosí
Country
Mexico
Facility Name
1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
City
San Luis Potosí
Country
Mexico
Facility Name
1160.26.1344 Boehringer Ingelheim Investigational Site
City
Almelo
Country
Netherlands
Facility Name
1160.26.1331 Boehringer Ingelheim Investigational Site
City
Amsterdam
Country
Netherlands
Facility Name
1160.26.1336 Boehringer Ingelheim Investigational Site
City
Apeldoorn
Country
Netherlands
Facility Name
1160.26.1332 Boehringer Ingelheim Investigational Site
City
Breda
Country
Netherlands
Facility Name
1160.26.1337 Boehringer Ingelheim Investigational Site
City
Den Bosch
Country
Netherlands
Facility Name
1160.26.1349 Boehringer Ingelheim Investigational Site
City
Den Helder
Country
Netherlands
Facility Name
1160.26.1345 Boehringer Ingelheim Investigational Site
City
Deventer
Country
Netherlands
Facility Name
1160.26.1360 Boehringer Ingelheim Investigational Site
City
Dirksland
Country
Netherlands
Facility Name
1160.26.1348 Boehringer Ingelheim Investigational Site
City
Dordrecht
Country
Netherlands
Facility Name
1160.26.1340 Boehringer Ingelheim Investigational Site
City
Ede
Country
Netherlands
Facility Name
1160.26.1358 Boehringer Ingelheim Investigational Site
City
Eindhoven
Country
Netherlands
Facility Name
1160.26.1338 Boehringer Ingelheim Investigational Site
City
Enschede
Country
Netherlands
Facility Name
1160.26.1343 Boehringer Ingelheim Investigational Site
City
Goes
Country
Netherlands
Facility Name
1160.26.1347 Boehringer Ingelheim Investigational Site
City
Gorinchem
Country
Netherlands
Facility Name
1160.26.1333 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
1160.26.1355 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
1160.26.1361 Boehringer Ingelheim Investigational Site
City
Heerlen
Country
Netherlands
Facility Name
1160.26.1339 Boehringer Ingelheim Investigational Site
City
Hengelo
Country
Netherlands
Facility Name
1160.26.1346 Boehringer Ingelheim Investigational Site
City
Hilversum
Country
Netherlands
Facility Name
1160.26.1356 Boehringer Ingelheim Investigational Site
City
Hoorn
Country
Netherlands
Facility Name
1160.26.1359 Boehringer Ingelheim Investigational Site
City
Maastricht
Country
Netherlands
Facility Name
1160.26.1341 Boehringer Ingelheim Investigational Site
City
Meppel
Country
Netherlands
Facility Name
1160.26.1354 Boehringer Ingelheim Investigational Site
City
Rotterdam
Country
Netherlands
Facility Name
1160.26.1351 Boehringer Ingelheim Investigational Site
City
Sneek
Country
Netherlands
Facility Name
1160.26.1334 Boehringer Ingelheim Investigational Site
City
Spiijkenisse
Country
Netherlands
Facility Name
1160.26.1335 Boehringer Ingelheim Investigational Site
City
Terneuzen
Country
Netherlands
Facility Name
1160.26.1353 Boehringer Ingelheim Investigational Site
City
Tiel
Country
Netherlands
Facility Name
1160.26.1352 Boehringer Ingelheim Investigational Site
City
Tilburg
Country
Netherlands
Facility Name
1160.26.1350 Boehringer Ingelheim Investigational Site
City
Veldhoven
Country
Netherlands
Facility Name
1160.26.1342 Boehringer Ingelheim Investigational Site
City
Velp
Country
Netherlands
Facility Name
1160.26.1357 Boehringer Ingelheim Investigational Site
City
Venlo
Country
Netherlands
Facility Name
1160.26.1396 Boehringer Ingelheim Investigational Site
City
Gjøvik
Country
Norway
Facility Name
1160.26.1393 Boehringer Ingelheim Investigational Site
City
Moss
Country
Norway
Facility Name
1160.26.1395 Boehringer Ingelheim Investigational Site
City
Nordbyhagen
Country
Norway
Facility Name
1160.26.1391 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1160.26.1392 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1160.26.1397 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1160.26.1394 Boehringer Ingelheim Investigational Site
City
RUD
Country
Norway
Facility Name
1160.26.1415 Hospital Alberto Sabogal
City
Bella Vista
Country
Peru
Facility Name
1160.26.1411 Clinica San Felipe
City
Jesús María
Country
Peru
Facility Name
1160.26.1412 Clínica Anglo Americana
City
San Isidro
Country
Peru
Facility Name
1160.26.1413 Hospital Cayetano Heredia
City
San Martín de Porres
Country
Peru
Facility Name
1160.26.1414 Clínica Vesalio
City
Urbanización Sto Tomas De San Borja
Country
Peru
Facility Name
1160.26.1421 Philippine General Hospital
City
Manila
Country
Philippines
Facility Name
1160.26.1422 Manila Doctors Hospital
City
Manila
Country
Philippines
Facility Name
1160.26.1424 The Medical City
City
Pasig City
Country
Philippines
Facility Name
1160.26.1423 Philippine Heart Center
City
Quezon City
Country
Philippines
Facility Name
1160.26.1425 St Lukes Medical Center
City
Quezon City
Country
Philippines
Facility Name
1160.26.1437 Boehringer Ingelheim Investigational Site
City
Gdynia Redlowo
Country
Poland
Facility Name
1160.26.1436 Boehringer Ingelheim Investigational Site
City
Gdynia
Country
Poland
Facility Name
1160.26.1438 Boehringer Ingelheim Investigational Site
City
Gdynia
Country
Poland
Facility Name
1160.26.1435 Boehringer Ingelheim Investigational Site
City
Katowice
Country
Poland
Facility Name
1160.26.1439 Boehringer Ingelheim Investigational Site
City
Krakow
Country
Poland
Facility Name
1160.26.1440 Boehringer Ingelheim Investigational Site
City
Krakow
Country
Poland
Facility Name
1160.26.1433 Boehringer Ingelheim Investigational Site
City
Pulawy
Country
Poland
Facility Name
1160.26.1431 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
1160.26.1432 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
1160.26.1434 Boehringer Ingelheim Investigational Site
City
Zabrze
Country
Poland
Facility Name
1160.26.1456 Boehringer Ingelheim Investigational Site
City
Amadora
Country
Portugal
Facility Name
1160.26.1451 Boehringer Ingelheim Investigational Site
City
Carnaxide
Country
Portugal
Facility Name
1160.26.1454 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1160.26.1459 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1160.26.1457 Boehringer Ingelheim Investigational Site
City
Covilhã
Country
Portugal
Facility Name
1160.26.1453 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1160.26.1458 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1160.26.1455 Boehringer Ingelheim Investigational Site
City
Porto
Country
Portugal
Facility Name
1160.26.1452 Boehringer Ingelheim Investigational Site
City
Setúbal
Country
Portugal
Facility Name
1160.26.1471 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1160.26.1472 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1160.26.1478 Boehringer Ingelheim Investigational Site
City
Cluj Napoca
Country
Romania
Facility Name
1160.26.1501 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1502 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1503 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1504 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1505 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1506 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1507 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1508 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1509 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1510 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1511 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.26.1512 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.26.1513 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.26.1514 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.26.1515 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.26.1531 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
1160.26.1532 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
1160.26.1548 Boehringer Ingelheim Investigational Site
City
Banska Bystrica
Country
Slovakia
Facility Name
1160.26.1541 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1542 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1543 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1544 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1545 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1546 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.26.1549 Boehringer Ingelheim Investigational Site
City
Kosice
Country
Slovakia
Facility Name
1160.26.1550 Boehringer Ingelheim Investigational Site
City
Kosice
Country
Slovakia
Facility Name
1160.26.1547 Boehringer Ingelheim Investigational Site
City
Zilina
Country
Slovakia
Facility Name
1160.26.1562 Boehringer Ingelheim Investigational Site
City
Bloemfontein
Country
South Africa
Facility Name
1160.26.1569 Boehringer Ingelheim Investigational Site
City
Boksburg
Country
South Africa
Facility Name
1160.26.1561 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
1160.26.1564 Boehringer Ingelheim Investigational Site
City
Johannesburg
Country
South Africa
Facility Name
1160.26.1567 Boehringer Ingelheim Investigational Site
City
Johannesburg
Country
South Africa
Facility Name
1160.26.1568 Boehringer Ingelheim Investigational Site
City
Johannesburg
Country
South Africa
Facility Name
1160.26.1566 Boehringer Ingelheim Investigational Site
City
Pretoria
Country
South Africa
Facility Name
1160.26.1563 Boehringer Ingelheim Investigational Site
City
Randburg
Country
South Africa
Facility Name
1160.26.1565 Boehringer Ingelheim Investigational Site
City
Somerset West
Country
South Africa
Facility Name
1160.26.1601 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1160.26.1606 Boehringer Ingelheim Investigational Site
City
Cadiz
Country
Spain
Facility Name
1160.26.1607 Boehringer Ingelheim Investigational Site
City
Fuenlabrada (Madrid)
Country
Spain
Facility Name
1160.26.1604 Boehringer Ingelheim Investigational Site
City
Leganés, Madrid
Country
Spain
Facility Name
1160.26.1609 Boehringer Ingelheim Investigational Site
City
Madrid-San Lorenzo Del Escorial
Country
Spain
Facility Name
1160.26.1603 Boehringer Ingelheim Investigational Site
City
Madrid
Country
Spain
Facility Name
1160.26.1608 Boehringer Ingelheim Investigational Site
City
Madrid
Country
Spain
Facility Name
1160.26.1605 Boehringer Ingelheim Investigational Site
City
Móstoles (Madrid)
Country
Spain
Facility Name
1160.26.1602 Boehringer Ingelheim Investigational Site
City
Sabadell
Country
Spain
Facility Name
1160.26.1633 Sahlgrenska Sjukhuset
City
Göteboerg
Country
Sweden
Facility Name
1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
City
Jönköping
Country
Sweden
Facility Name
1160.26.1631 Universitetssjukhuset i Linköping
City
Linköping
Country
Sweden
Facility Name
1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
City
Malmö
Country
Sweden
Facility Name
1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
City
Norrköping
Country
Sweden
Facility Name
1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
City
Nässjö
Country
Sweden
Facility Name
1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
City
Stockholm
Country
Sweden
Facility Name
1160.26.1632 Capio S:t Görans Sjukhus
City
Stockholm
Country
Sweden
Facility Name
1160.26.1634 Södersjukhuset
City
Stockholm
Country
Sweden
Facility Name
1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
City
Umeå
Country
Sweden
Facility Name
1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
City
Uppsala
Country
Sweden
Facility Name
1160.26.1635 UCR/Uppsala
City
Uppsala
Country
Sweden
Facility Name
1160.26.1622 Hjärtmottagningen, Centrallasarettet
City
Västerås
Country
Sweden
Facility Name
1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
City
Örebro
Country
Sweden
Facility Name
1160.26.1652 Boehringer Ingelheim Investigational Site
City
Basel
Country
Switzerland
Facility Name
1160.26.1655 Boehringer Ingelheim Investigational Site
City
Bellinzona
Country
Switzerland
Facility Name
1160.26.1651 Boehringer Ingelheim Investigational Site
City
Bern
Country
Switzerland
Facility Name
1160.26.1654 Boehringer Ingelheim Investigational Site
City
Lugano
Country
Switzerland
Facility Name
1160.26.1680 Boehringer Ingelheim Investigational Site
City
Changhua County
Country
Taiwan
Facility Name
1160.26.1683 Boehringer Ingelheim Investigational Site
City
Hualien
Country
Taiwan
Facility Name
1160.26.1682 Boehringer Ingelheim Investigational Site
City
Kaohsiung
Country
Taiwan
Facility Name
1160.26.1679 China Medical University Hospital
City
Taichung
Country
Taiwan
Facility Name
1160.26.1681 Boehringer Ingelheim Investigational Site
City
Tainan
Country
Taiwan
Facility Name
1160.26.1671 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1672 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1673 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1674 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1675 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1676 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1677 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.26.1678 Boehringer Ingelheim Investigational Site
City
Taoyuan
Country
Taiwan
Facility Name
1160.26.1701 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
1160.26.1702 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
1160.26.1703 Boehringer Ingelheim Investigational Site
City
Chiangmai
Country
Thailand
Facility Name
1160.26.1704 Boehringer Ingelheim Investigational Site
City
Khon Kaen
Country
Thailand
Facility Name
1160.26.1705 Boehringer Ingelheim Investigational Site
City
Muang Nakhonratchasima
Country
Thailand
Facility Name
1160.26.1715 Boehringer Ingelheim Investigational Site
City
Adana
Country
Turkey
Facility Name
1160.26.1711 Boehringer Ingelheim Investigational Site
City
Ankara
Country
Turkey
Facility Name
1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
City
Ankara
Country
Turkey
Facility Name
1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
City
Izmir
Country
Turkey
Facility Name
1160.26.1727 Boehringer Ingelheim Investigational Site
City
Dnyepropetrovsk
Country
Ukraine
Facility Name
1160.26.1726 Boehringer Ingelheim Investigational Site
City
Kharkiv
Country
Ukraine
Facility Name
1160.26.1724 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1160.26.1725 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1160.26.1721 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1722 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1723 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1728 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1730 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1731 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1160.26.1729 Boehringer Ingelheim Investigational Site
City
Lvov
Country
Ukraine
Facility Name
1160.26.1744 Boehringer Ingelheim Investigational Site
City
Birmingham
Country
United Kingdom
Facility Name
1160.26.1746 Boehringer Ingelheim Investigational Site
City
Chertsey
Country
United Kingdom
Facility Name
1160.26.1747 Boehringer Ingelheim Investigational Site
City
Glasgow
Country
United Kingdom
Facility Name
1160.26.1750 Boehringer Ingelheim Investigational Site
City
Harrow
Country
United Kingdom
Facility Name
1160.26.1753 Boehringer Ingelheim Investigational Site
City
Hull
Country
United Kingdom
Facility Name
1160.26.1755 Boehringer Ingelheim Investigational Site
City
Kirkcaldy, Fife
Country
United Kingdom
Facility Name
1160.26.1749 Boehringer Ingelheim Investigational Site
City
Londonderry
Country
United Kingdom
Facility Name
1160.26.1741 Boehringer Ingelheim Investigational Site
City
London
Country
United Kingdom
Facility Name
1160.26.1756 Boehringer Ingelheim Investigational Site
City
London
Country
United Kingdom
Facility Name
1160.26.1742 Boehringer Ingelheim Investigational Site
City
Newcastle upon Tyne
Country
United Kingdom
Facility Name
1160.26.1751 Boehringer Ingelheim Investigational Site
City
Newport
Country
United Kingdom
Facility Name
1160.26.1752 Boehringer Ingelheim Investigational Site
City
Northampton
Country
United Kingdom
Facility Name
1160.26.1745 Boehringer Ingelheim Investigational Site
City
Portadown, County Atrim
Country
United Kingdom
Facility Name
1160.26.1743 Boehringer Ingelheim Investigational Site
City
Romford, Essex
Country
United Kingdom
Facility Name
1160.26.1754 Boehringer Ingelheim Investigational Site
City
Stoke-On-Trent
Country
United Kingdom
Facility Name
1160.26.1748 Boehringer Ingelheim Investigational Site
City
York
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
34411158
Citation
Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
Results Reference
derived
PubMed Identifier
34358298
Citation
Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
Results Reference
derived
PubMed Identifier
33757788
Citation
Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
Results Reference
derived
PubMed Identifier
33741689
Citation
Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
Results Reference
derived
PubMed Identifier
33292046
Citation
Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
Results Reference
derived
PubMed Identifier
32984892
Citation
Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
Results Reference
derived
PubMed Identifier
32385506
Citation
Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
Results Reference
derived
PubMed Identifier
31046423
Citation
Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
Results Reference
derived
PubMed Identifier
30651032
Citation
Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
Results Reference
derived
PubMed Identifier
30012318
Citation
Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
Results Reference
derived
PubMed Identifier
29653640
Citation
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
Results Reference
derived
PubMed Identifier
29069359
Citation
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
Results Reference
derived
PubMed Identifier
28520924
Citation
Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
Results Reference
derived
PubMed Identifier
28213368
Citation
Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17.
Results Reference
derived
PubMed Identifier
27569438
Citation
Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
Results Reference
derived
PubMed Identifier
27496855
Citation
Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.
Results Reference
derived
PubMed Identifier
27056738
Citation
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
Results Reference
derived
PubMed Identifier
26818781
Citation
Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28.
Results Reference
derived
PubMed Identifier
26678637
Citation
Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3.
Results Reference
derived
PubMed Identifier
26093161
Citation
Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.
Results Reference
derived
PubMed Identifier
26065986
Citation
Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.
Results Reference
derived
PubMed Identifier
24794140
Citation
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014 Aug;100(15):1193-200. doi: 10.1136/heartjnl-2013-304872. Epub 2014 May 2.
Results Reference
derived
PubMed Identifier
24359765
Citation
Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, Pogue J, Wallentin L, Ezekowitz MD, Connolly SJ, Yusuf S; RE-LY Study Investigators. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. Epub 2013 Nov 23.
Results Reference
derived
PubMed Identifier
24323795
Citation
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
Results Reference
derived
PubMed Identifier
24081972
Citation
Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
Results Reference
derived
PubMed Identifier
24076487
Citation
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27.
Results Reference
derived
PubMed Identifier
24016454
Citation
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9.
Results Reference
derived
PubMed Identifier
23770182
Citation
Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.
Results Reference
derived
PubMed Identifier
23743976
Citation
Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.
Results Reference
derived
PubMed Identifier
23467860
Citation
Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.
Results Reference
derived
PubMed Identifier
23271794
Citation
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
Results Reference
derived
PubMed Identifier
23103906
Citation
Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, Aisenberg J. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
Results Reference
derived
PubMed Identifier
23027801
Citation
Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1.
Results Reference
derived
PubMed Identifier
22700854
Citation
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum In: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].
Results Reference
derived
PubMed Identifier
22374183
Citation
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28.
Results Reference
derived
PubMed Identifier
22215856
Citation
Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.
Results Reference
derived
PubMed Identifier
22084332
Citation
Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.
Results Reference
derived
PubMed Identifier
21576658
Citation
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
Results Reference
derived
PubMed Identifier
21200007
Citation
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3.
Results Reference
derived
PubMed Identifier
21147728
Citation
Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.
Results Reference
derived
PubMed Identifier
21059484
Citation
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6. Erratum In: Lancet Neurol. 2011 Jan;10(1):27.
Results Reference
derived
PubMed Identifier
20801496
Citation
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.
Results Reference
derived
PubMed Identifier
19717844
Citation
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum In: N Engl J Med. 2010 Nov 4;363(19):1877.
Results Reference
derived
PubMed Identifier
19376304
Citation
Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.26_U09-3249.pdf
Description
Related Info

Learn more about this trial

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

We'll reach out to this number within 24 hrs